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ABSTRACT
Kaposi’s sarcoma herpesvirus (KSHV) is a human gamma2-herpesvirus and the causative agent of
three human cancers: Kaposi’s sarcoma (KS), primary effusion lymphoma (PEL) and multicentric
Castleman’s disease (MCD). KSHV establishes persistent life-long infection and manipulates host
cell proliferation and apoptosis, which leads to the development of cancer in immunocompromised
individuals. KSHV has two phases of life cycle, the latency phase and lytic replication phase.
Latency is a silent mode of infection, while in the lytic replication phase new virus progeny are
produced. Although the latent phase is the default mode of infection, the lytic cycle has an
instrumental role in the emergence and progression of KS.
KSHV  encodes  several  microRNAs  (miRNAs)  that  have  a  potential  role  in  viral  tumorigenesis.
However, the targets of these miRNAs are still poorly known. In the first study we show that
KSHV-encoded miRNAs inhibit apoptosis by silencing the expression of caspase 3, an apoptotic
effector, in latent KSHV-infected cells.
In the second study the aim is to discover new specific anti-viral drugs by targeting host cell anti-
apoptotic mechanisms utilized by KHSV. To this end, BH3 mimetic drugs are tested which bind
and inhibit the anti-apoptotic function of the B-cell lymphoma 2 (Bcl-2) family of proteins in
KSHV-infected cells. This study shows that the myeloid cell leukemia-1 (Mcl-1) inhibitor,
Obatoclax, induces cell death in KSHV-infected cells undergoing lytic phase.
The cellular mechanisms that regulate the triggering of the lytic cycle (reactivation) are not
completely understood. To discover new regulators of KSHV reactivation and lytic cycle activation,
a targeted RNAi screen was performed using a library of siRNA oligos targeting human epigenetic
factors and their regulators. The screen identifies Mouse double minute-2 (MDM2), the main
regulator of p53 protein stability, as a negative regulator of KSHV reactivation. Further studies
demonstrate  that  efficient  KSHV  reactivation  is  favored  by  a  p53  stress  response  and  by  the
induction of p21Cip-1-mediated G2/M cell cycle arrest.
KSHV encoded cyclin D homolog viral cyclin (v-cyclin) is able to overcome G1 cell cycle arrest
and dysregulate mitosis of KSHV infected cells. V-cyclin operates by interacting with cellular
proteins and consequently to study the role of v-cyclin in KSHV induced cancers, comprehensive
interactome of v-cyclin and cellular proteins was studied in tetracycline inducible isogenic v-cyclin
expressing human cell line.
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In summary, research in this thesis identifies a new cellular target of KSHV-encoded miRNAs and
uncovers a cellular anti-apoptotic mechanism utilized by this virus to protect cells undergoing lytic
replication from premature death. Inhibition of this mechanism enabled the identification of a
potential new drug candidate against KSHV-associated cancers. Additionally, this study provides
new insights into how KSHV can cope with and utilize cellular stress response to ensure efficient
lytic replication and revealed 8 novel v-cyclin interacting cellular proteins.
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REVIEW OF THE LITERATURE
Like other herpesviruses, KSHV infection results in extensive alterations of cellular processes such
as apoptosis, the DNA-damage response and cell cycle progression (Mesri, Cesarman et al. 2010).
The molecular details of these alterations, the implications for virus replication and associated
diseases, and the possibility to interfere with these processes as a potential therapeutic strategy are
the main topics of this thesis.
1. Programmed cell death
Apoptosis is a tightly regulated cellular process leading to cell death. It is characterized by a series
of changes in cell morphology and structure, including cell membrane blebbing, the collapse of the
nucleus into dense structures, and the fragmentation of the chromosomal DNA (Kerr, Wyllie et al.
1972,  Kroemer,  El-Deiry  et  al.  2005)  and  of  the  whole  cell  to  form  apoptotic  bodies.  These
apoptotic bodies are 1-5 m vesicular structures that are rapidly ingested by neighboring cells or by
macrophages due to the exposure of the signaling lipid phosphatidylserine (Golstein 1998,
Hengartner 2000). Apoptosis is a physiological process that occurs during embryogenensis,
lymphocyte development and tissue maintenance, and can also be induced by several cell stresses
such as oncogene hyperactivation, virus infection, Ultraviolet (UV) radiation and DNA damage.
The main executors of the apoptotic program are cysteine proteases called caspases (Yuan, Shaham
et al. 1993, Nicholson, Ali et al. 1995). These enzymes can be activated by the intrinsic
(mitochondrial-mediated) or extrinsic (death receptor-mediated) apoptotic pathways (Figure 1).
1.1. Caspases
Caspases are synthesized in an inactive zymogenic pro-enzyme form and are activated by
proteolytic cleavage. Caspases consist of two domains: the N-terminal pro-domain, which is
important for caspase regulation, and the C-terminal protease domain, which carries catalytic
activity. Apoptotic caspases can be divided into two groups: initiators and effectors. Initiator
caspases, such as caspases-8 and -9, are activated by adaptor proteins which interact with the pro-
domain and promote caspase dimerization and activation (Boatright, Renatus et al. 2003, Pop,
Timmer et al. 2006). Effector caspases, such caspases-3and -6, have a shorter pro-domain and are
activated by the initiator caspases through proteolytic cleavage. Once activated, effector caspases
cleave cellular substrates such as lamin and Poly (ADP-ribose) polymerase (PARP). These and
other cleavage events initiate the dismantling of the cell (Mahrus, Trinidad et al. 2008).
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1.2. Intrinsic pathway
The intrinsic apoptosis pathway (Figure 1) refers to programmed cell death initiated by a series of
reactions that lead to the disruption of the mitochondrial membrane and the release of cytochrome-
C into the cytoplasm, which induces the activation cascade of caspases starting from initiator
caspases such as caspases-2, -8, -9 and -10 (Ashkenazi and Salvesen 2014).
Intrinsic apoptosis is regulated by the Bcl-2 family of proteins, which includes both pro- and anti-
apoptotic members. Whether they induce or inhibit apoptosis depends on what structural domains
they contain. The type and number of structural domains are used to categorize Bcl-2 family
members into three functional sub-groups: i) initiators of apoptosis or "BH-3-only" proteins ii) pro-
apoptotic effector proteins and iii) anti-apoptotic proteins. Apoptotic signals such as DNA damage
and growth factor deprivation activate the initiator BH3-only proteins such as Bcl-2-interacting
mediator of cell death (Bim) and Bcl-2-antagonist of cell death (Bad), which inactivate anti-
apoptotic Bcl-2 family proteins such as Bcl-2, B-cell lymphoma-extra large (Bcl-XL) and Mcl-1.
This results in the activation of the pro-apoptotic effector proteins Bcl-2-associated X protein (Bax)
and Bcl-2  antagonist  killer  (Bak).  Active  Bax  and  Bak  are  proteins  that  form  pores  on  the  outer
mitochondrial membrane causing the release of cytochrome C (Czabotar, Lessene et al. 2014).
Released cytochrome C induces the formation of the apoptosome, a large protein complex that
includes apoptotic protease-activating factor 1 (Apaf-1) and is responsible for recruiting and
activating procaspase-9 (Li, Nijhawan et al. 1997, Kroemer, Galluzzi et al. 2007). Activated
caspase-9 cleaves and activates effector caspase-3, which cleaves other effector caspases, including
-6 and -7, leading to the execution of apoptosis.
1.3. Extrinsic pathway
Extrinsic apoptosis (Figure 1) is induced by the activation of plasma membrane receptors called
death receptors. These receptors belong to the tumor necrosis factor receptor (TNFR) superfamily
and contain the death domain (DD).  The death receptors which can induce apoptosis via caspase
activation are TNF Receptor Superfamily, Member 6 (Fas), TNFR1, death receptor 3 (DR3), death
receptor 4 (DR4), death receptor 5 (DR5) and death receptor 6 (DR6) (Locksley, Killeen et al. 2001,
Lavrik, Golks et al. 2005). Binding of death ligands such as Fas (FasL) and tumor necrosis factor α
(TNFα) causes a conformational change of the death receptor and exposes the DD domain, which
recruits adaptor proteins such as Fas-associated DD protein (FADD) and TNFR-associated DD
protein (TRADD). Adaptor proteins bind pro-caspase-8 (also known as FLICE) through their death
effector domains (DED) and form the death-inducing signaling complex (DISC), which triggers
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caspase activation (Wallach, Varfolomeev et al. 1999, Schneider and Tschopp 2000, Wong 2011).
Activated caspase-8 cleaves and activates effector caspases 3, 6 and 7 (Hirata, Takahashi et al.
1998, Kruidering and Evan 2000). Additionally, caspase-8 can cleave Bid, forming truncated Bid
(tBid), which translocates to the mitochondria and causes release of cytochrome C into the
cytoplasm (Li, Zhu et al. 1998, Luo, Budihardjo et al. 1998).
Figure 1. Intrinsic and extrinsic apoptosis pathways.
1.4. Anti-apoptotic mechanisms
The extracellular environment and the signals the cell receives from it determine whether it dies or
survives. Biochemically, it is defined by the balance of pro-apoptotic and anti-apoptotic factors.
Extracellular signals such as growth factors, chemokines, hormones and contacts with the extra
cellular matrix (ECM) typically promote cell survival by activating intracellular anti-apoptotic
factors. These anti-apoptotic factors function at multiple levels, inhibiting both extrinsic and
intrinsic apoptosis pathways by antagonizing caspases or pro-apoptotic Bcl-2 proteins, or by
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promoting the expression of anti-apoptotic genes after having activated the transcription factor
nuclear factor kappa-B (NF-κB) (Portt, Norman et al. 2011).
Apoptosis can be inhibited by Inhibitor of Apoptosis proteins (IAP), such as X-linked inhibitor of
apoptosis (XIAP), which can bind and inhibit caspases-3, -7 and -9. Pro-apoptotic stimuli cause the
release of second mitochondria-derived activator of caspases (SMAC/DIABLO) from the
mitochondria, which inhibits the IAPs to promote cytochrome C-induced caspase activation
(Deveraux and Reed 1999, LaCasse, Mahoney et al. 2008).
Cellular FLICE-inhibitory protein (cFLIP) is another inhibitor of apoptosis and is homologous to
procaspase-8.  cFLIP  contains  two  DED-domains,  which  enable  it  to  bind  to  the  FADD  and  the
DISC  complex.  cFLIP  has  two  mRNA  isoforms:  the  short  form  (cFLIPS) and the long form
(cFLIPL). cFLIPS lacks a catalytic domain, thus it competes with procaspase-8 for DISC binding
and hence inhibits procaspase-8 cleavage. The cFLIPL variant can heterodimerize with procaspase-8
and promote its activation (Chang, Xing et al. 2002), however, it has been recently shown that these
heterodimers promote cell survival (Oberst, Dillon et al. 2011, van Raam and Salvesen 2012),
underscoring the complexity of apoptotic regulation.
NF-κB is a transcription factor that regulates cell survival and is activated mainly by TNFα. As
mentioned earlier, TNFα induces apoptosis via TNFR, but in addition to that, TNFR can also induce
anti-apoptotic pathways by binding to the TNF receptor-associated factor 2 (TRAF2) protein, which
in turn recruits Receptor-interacting serine/threonine-protein kinase 1 (RIP1) and activates NF-κB.
Additionally, TNFα can activate the Phosphoinositide 3-kinase (PI3K)/Akt/Protein kinase B (PKB)
kinase pathway, which results in the phosphorylation and activation of the IκB kinase (IKK) kinase
complex, which in turn phosphorylates and inactivates the inhibitor κB (IκB) and causes activation
of  NF-κB.  NF-κB activates  the  expression  of  anti-apoptotic  genes  such  as  Bcl-XL and XIAP and
therefore promotes cell survival (Barkett and Gilmore 1999, Brenner, Blaser et al. 2015).
1.5. Signaling pathways regulating apoptosis
Apoptosis and cell survival is regulated by signaling pathways which are responsive to extracellular
signals such as mitogens and stress inducers. Extracellular signal-regulated kinase (ERK) and C-Jun
N-terminal protein kinase (JNK)/p38 pathways forms regulatory network where ERK promotes cell
survival by inhibiting pro-apoptotic function of JNK/p38 pathway whereas JNK/p38 inhibits ERK
pathway when encountering stress signals. Stress induce apoptosis via p38/JNK mediated activation
of protein phosphatase 2A (PP2A) and MAPK phosphatase (MKP) which negatively regulate ERK
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pathway (Junttila, Li et al. 2008). These pathways regulate stability and activity of pro- and anti-
apoptotic proteins.
Phosphorylation status of Bim determinates its function and stability. Phosphorylation of Bim by
ERK1,2 lead to its proteasomal degradation whereas phosphorylation by JNK or p38 increase its
pro-apoptotic activity (Putcha, Le et al. 2003, Okuno, Saito et al. 2004, Ley, Ewings et al. 2005,
Cai, Chang et al. 2006). Furthermore protein kinase A (PKA) activates Bim by phosphorylating
cAMP response element-binding protein (CREB) (Zhang and Insel 2004).
ERK1,2 mediates cell survival by co-operating with ribosomal S6 kinase (RSK) to phosphorylate
Bim which lead to its ubiquitin mediated degradation (Dehan, Bassermann et al. 2009). Furthermore
RSK kinase can activate CREB transcription factor which upregulate expression of Bcl-2 and Bcl-
xL (Bonni, Brunet et al. 1999). Moreover ERK1,2  is able to phosphorylate and inhibit caspase-9
(Allan, Morrice et al. 2003). ERK signaling is also inhibiting extrinsic apoptosis by inhibiting Fas
induced DISC formation (Holmstrom, Schmitz et al. 2000). Also epidermal growth factor receptor
(EGFR) activated Src kinase has been found to phosphorylate caspase-8 and prevent extrinsic
apoptosis upon growth factor stimulation (Cursi, Rufini et al. 2006).
It has been shown that growth promoting cytokine interleukin-3 (IL-3) activates ERK mediated
phosphorylation of Bim, which dissociates it from Bax and inhibits its pro-apoptotic function
(Harada, Quearry et al. 2004). Also IL-3 activated PI3K/Akt phosphorylates Bad and inhibits
apoptosis (Zha, Harada et al. 1996, Datta, Dudek et al. 1997, del Peso, Gonzalez-Garcia et al.
1997). Akt is also downregulating expression of Bim by phosphorylating and inactivating
transcription factor (TF) forkhead box O3a (FoxO3a) which is needed for Bim transcription
(Dijkers, Medema et al. 2000, Tzivion, Dobson et al. 2011).
Growth factor deprivation and cellular stress activates pro-apoptotic proteins. Interlukin-2 (IL-2)
deprivation lead to phosphatase type 1 alpha (PP1α) mediated de-phosphorylation and activation of
caspase-9 (Dessauge, Cayla et al. 2006) and DNA damage induces phosphorylation of caspase-9 at
Tyr153 by c-Abl kinase which leads to activation of caspase-9 and induction of apoptotic response
(Raina, Pandey et al. 2005).
1.6. Apoptosis in cancer
One of the functions of  apoptosis is to eliminate neoplastic and potentially malignant cells (Kerr,
Wyllie et al. 1972). Thus, evasion of the apoptotic program is one of the hallmarks of the multistep
tumorigenesis process (Hanahan and Weinberg 2000, Hanahan and Weinberg 2011). Cancer cells
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can evade apoptosis by multiple mechanisms such as disrupting the balance between anti- and pro-
apoptotic Bcl-2 family proteins, attenuation of caspase function and reduction of death receptor
function. In many cancers, anti-apoptotic Bcl-2 family proteins have been found to be
overexpressed, which correlates with poor prognosis and resistance to chemotherapy (Tsujimoto,
Finger et al. 1984, Raffo, Perlman et al. 1995, Friess, Lu et al. 1998, Taniai, Grambihler et al. 2004,
Wuilleme-Toumi, Robillard et al. 2005, Beroukhim, Mermel et al. 2010). Conversely, pro-apoptotic
Bcl-2 proteins such as Bax and Bim and p53 upregulated modulator of apoptosis (PUMA) have
been found to be downregulated in certain cancers (Rampino, Yamamoto et al. 1997, Beroukhim,
Mermel et  al.  2010, Ng, Hillmer et  al.  2012).  Cancer cells can prevent initiation and execution of
apoptosis by reducing caspase activity, and it has been reported that caspase levels are reduced in
many malignancies. In addition, caspases-8 and -3 are frequently mutated in several cancers
(Ghavami, Hashemi et al. 2009). Moreover loss of Apaf-1 expression have been identified in many
cancer and it is associated with poor prognosis (Dai, Martinka et al. 2004, Fujimoto, Takeuchi et al.
2004, Wang, Bai et al. 2007, Zlobec, Minoo et al. 2007) Cancer cells can evade death signals by
downregulating the expression of death receptors or impairing their function, and additionally, they
can decrease the secretion of death ligands (Debatin and Krammer 2004). Conventional cancer
therapies such as chemotherapy and γ-irradiation aim at inducing apoptosis in cancer cells, but
defective apoptotic mechanisms of tumor cells may cause drug resistance. Therefore targeting
apoptotic mechanisms could provide new therapeutic modalities to fight cancer and currently one of
the  most  promising  sets  of  targets  seems  to  be  the  Bcl-2  family  of  proteins.  Small-molecule
inhibitors such as ABT-737, ABT-263, ABT-199 and Obatoclax are BH-3 mimetic drugs, which
induce apoptosis by binding Bcl-2, Bcl-XL, Bcl-w and Mcl-1, preventing their interaction with pro-
apoptotic proteins (Wong 2011, Moldoveanu, Follis et al. 2014). The apoptotic function of ABT-
737 is synergized with kinase inhibitors as in the study where ABT-737 was combined with kinase
inhibitor Sorafinib, co-treatment suppressed growth of hepatocellular cancer cells and xenograft
tumors (Hikita, Takehara et al. 2010). And furthermore inhibition of PI3K/ mammalian target of
rapamycin (mTOR) pathway synergize ABT-737 apoptotic effect on ovarian cancer cells and
myeloid leukemia cells (Rahmani, Aust et al. 2013, Jebahi, Villedieu et al. 2014). ABT-263 is
clinical derivative of ABT-737 and it is currently undergoing phase I and II clinical studies in
treatment of multiple cancer types (Wilson, O'Connor et al. 2010, Cleary, Lima et al. 2014, Kipps,
Eradat et al. 2015). ABT-199 is recently developed derivative, which does not cause
thrombocytopenia like ABT-737 and ABT-236 (Souers, Leverson et al. 2013). ABT-199 enhances
anti-cancer effect of tamoxifen in breast cancer xenografts (Vaillant, Merino et al. 2013). Moreover
ABT-199 was shown to be promising against multiple myeloma and chronic lymphocytic leukemia
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(Vogler, Dinsdale et al. 2013, Touzeau, Dousset et al. 2014). Phase I clinical trial to treat relapsed
chronic lymphocytic leukemia with ABT-199 revealed manageable safety profile and remarkable
response (Roberts, Davids et al. 2016). And importantly ABT-199 is recently approved by food and
drug administration (FDA) to treat chronic lymphocytic leukemia patients with chromosome 17p
deletion. Obatoclax is inhibiting Bcl-2, Bcl-w, Bcl-xL and Mcl-1 (Nguyen, Marcellus et al. 2007).
Obatoclax induce apoptosis, autophagy and necroptosis of acute lymphoblastic leukemia (ALL) cell
lines (Urtishak, Edwards et al. 2013) and increased sensitivity of multiple myeloma cells to
chemotherapeutic agents (Trudel, Li et al. 2007).
2. Cell cycle
Cell division is part of a cellular process referred to as the cell cycle. This highly regulated process
consists  of  four  different  phases:  Gap 1  (G1),  synthesis  phase  (S-phase),  Gap 2  (G2)  and  mitosis
(M-phase) (Figure 2). The progression from one phase to the other is mainly coordinated by cyclin
proteins and the associated cyclin-dependent kinases (Cdks). The levels of cyclin proteins oscillate
during the cell cycle and specific cyclins are expressed in each cell cycle phase (Evans, Rosenthal et
al. 1983). Cyclins bind and activate Cdks, which regulate cell cycle progression by phosphorylating
their target proteins (Morgan 1995). Cdk activity can be modulated by phosphorylation. Full kinase
activity of Cdk-cyclin complex can be reached by phosphorylation by Cdk-activating kinase (CAK)
(Nigg 1996). And on the other hand phosphorylation of Cdks at Thr14 and/or Tyr15 residues by
Wee1 and Myelin transcription factor 1 (Myt1) kinases inhibit its activity while Cell division cycle
25 (Cdc25) phosphatases can dephosphorylate these residues in order to activate Cdks when
required (Malumbres 2014). During G1, a cell grows and prepares itself for the next step of the cell
cycle. At the transition between one cell cycle phase and another there exist quality control
mechanisms, or checkpoints, to ensure that no 'mistakes' have been made and that cells can proceed
towards division.  At the G1 checkpoint, cells need to ensure that cell size is sufficient, that the
genome is intact, and that an adequate amount of mitogens are present to move into S-phase. Failing
this checkpoint activates a restriction mechanism known as the G1 restriction or R-point. G1-phase
progression  is  regulated  by  cyclin  D  as  well  as  the  Cdk4  and  6  kinases.  When  sufficient  growth
factor stimulation exists, cyclin D is expressed and it associates with Cdk4 and 6 (Bottazzi and
Assoian 1997). CyclinD/Cdk4 and 6 phosphorylate the retinoblastoma protein (pRb) that gets
inactivated (Figure 2). pRb is a 'pocket' protein which acts as a co-repressor together with histone
deacetylase 1 (HDAC1) to repress the expression of the transcription factor E2 factor (E2F), which
is a main activator of cell cycle progression. Thus, when the repressor pRb is phosphorylated, E2F
is  de-repressed  and  is  able  to  initiate  transcription  of  genes  required  for  promoting  cell  cycle
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progression  from G1 to  S-phase.  Some of  the  targets  of  E2F include  cyclins  E  and  A,  as  well  as
proteins required in S-phase for DNA replication (Vermeulen, Van Bockstaele et al. 2003).  Cyclin
E binds Cdk2 and the active cyclin E/Cdk2 complex is responsible for G1/S progression.
During S-phase, the DNA genome of the cell is duplicated and cells need to ensure that this process
occurs flawlessly and only once during each cell division. This is monitored during checkpoints that
are also in place during S-phase and at the S/G2 transition. After DNA replication is completed,
cells  enter  into  G2  phase,  where  they  prepare  to  enter  mitosis  by  condensing  the  DNA  into
chromosomes. If the replicated DNA is intact and the condensed chromosomes formed correctly,
cells proceed to mitosis (M-phase). The integrity of replicated DNA is monitored at the onset of the
G2 phase, before DNA condensation. If the DNA is damaged, the DNA-damage checkpoint is
activated and the cell cycle stops in early G2 to allow DNA repair (Malumbres and Barbacid 2009).
Once the damaged DNA is repaired, the accumulated cyclin B binds Ckd1 and cells prepare to enter
mitosis. The phosphatase Cdc25 activates the complex by dephosphorylating Cdk1.
Mitosis is subdivided into five distinct phases called prophase, prometaphase, metaphase, anaphase
and telophase. During prophase, the genome is condensed into chromosomes, and the centrosomes,
located at the opposite sides of the nucleus, begin to polymerize microtubules to form the mitotic
spindle, a macromolecular structure that segregates the duplicated chromosomes to each side of the
dividing cell. During prometaphase, the nuclear envelope is disintegrated, allowing microtubules to
attach to the central portion of each chromosome, the kinetochores, forming the mitotic spindle. The
mitotic spindle is composed of polar microtubules which are attached from the one end to the
centrosome and from the other end to the kinetochore of each chromosome. During metaphase,
chromosomes align at the center of the dividing cell, forming the metaphase plate (Malumbres and
Barbacid 2009). To ensure correct alignment of chromosomes and secure the proper attachment of
kinetochores, mitosis can be stopped by the spindle assembly checkpoint (SAC), which inhibits the
anaphase promoting complex (APC/C) protein (Burke and Stukenberg 2008). APC/C is an E3
ubiquitin ligase responsible for the metaphase-to-anaphase transition. APC/C targets cyclins A and
B as well as Securin proteins for proteolytic degradation. After securin degradation, separin proteins
are activated, enabling segregation of sister chromatids by the hydrolysis of  cohesins, which  link
the sister chromatids together (Peters 2002). Thus, during anaphase, sister chromatids are pulled
apart with the help of shortening microtubules. Finally, in telophase, the nuclear envelope reforms
around each daughter chromosome and the DNA is decondensed. Thereafter, the two daughter cells
separate from each other by a process called cytokinesis. This last step of the cell cycle is achieved
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by a contractile ring of actin filaments, which cleaves the cell in two (Malumbres and Barbacid
2009).
Figure 2. Regulation of the cell cycle.
2.1. Cdk inhibitory proteins
Cdk inhibitory proteins (CKIs) exist in every cell to regulate the cell cycle and prevent abnormal
cell  proliferation and potential  cellular transformation (Figure 2).  There are two families of CKIs:
INK4 and Cip/Kip. The INK4 family includes the cell cycle progression inhibitors p15INK4b,
p16INK4a, p18INK4c and p19INK4d, which inhibit Cdk4 and 6, causing G1 cell cycle arrest. At the
molecular level, the INK4 inhibitors cause a conformational change in Cdk protein structure that
inhibits the catalytic activity of the enzyme. Additionally, by binding to the G1-specific Cdks, INK4
inhibitors block the interaction of the kinases with their respective cyclin, cyclin-D (Russo, Tong et
al. 1998). Interestingly, INK4 inhibitors are able to arrest the cell cycle in G1-phase only if the E2F
inhibitor pRb protein is functional (Bruce, Hurford et al. 2000).
Various stress signals in G1 phase can trigger INK4 protein activation. For instance, the expression
of p15INK4b and p16INK4a can be activated by oncogenic stress. The transcription factor JunB has
been shown to transactivate the expression of p16INK4a and induce premature senescence of mouse
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3T3 cells (Passegue and Wagner 2000). Moreover, Ets-domain transcription factor (Ets) activates
the expression of p16INK4a in senescent human fibroblast cells (Ohtani, Zebedee et al. 2001),
whereas p15INK4b expression is induced by transforming growth factor β (TGFβ) in epithelial cells
(Hannon and Beach 1994).
The Cip/Kip family consists of p21Cip1, p27Kip1 and p57Kip2. Like the INK4 proteins, these inhibitors
inactivate Cdk/cyclin complexes, but in a different manner, through binding to both cyclin and Cdk.
Also, they seem to have a broader range. They inhibit the G1/S transition by forming a ternary
complex with cyclinE/A/Ckd2. In addition, some of the Clip/Kip family members can induce cell
cycle arrest in G2 after DNA damage (Bunz, Dutriaux et al. 1998, Smits, Klompmaker et al. 2000).
p21Cip1 has also been shown to inhibit DNA replication by inhibiting the activity of proliferating cell
nuclear antigen (PCNA) (Li, Waga et al. 1994, Cazzalini, Scovassi et al. 2010). The expression
levels of p21Cip1 are mainly regulated by the stress-sensor p53 (a transcription factor) (el-Deiry,
Tokino et al. 1993).
 p27Kip1 expression is regulated by growth inhibitory cytokines, contact inhibition and by several
transcription factors like FoxO, specifity protein 1 (Sp1) and breast cancer susceptibility gene 1
(BRCAI) (Roy and Banerjee 2015). p27Kip1 has a role in the maintenance of a quiescent phase of
cells and the regulation of cell proliferation during organ development (Fero, Rivkin et al. 1996).
Interestingly, studies with heterozygous null mice of p27Kip1 have revealed that it is
haploinsufficient for tumor suppressor activity (Fero, Randel et al. 1998).
CyclinD/Cdk4/6 promotes cell cycle progression by binding to Cip/Kip family inhibitors to prevent
inhibition of cyclinE/Cdk2 complex. In addition, by binding and sequestering Cdk4/6, the INK4
inhibitors can increase the pool of free p27Kip and promote more efficient inhibition of
cyclinE/Ckd2 complex (Sherr and Roberts 1995). Knock-out studies have revealed that INK4 and
Cip/Kip inhibitors cooperate in tumor suppression in a tissue-specific manner (Franklin, Godfrey et
al. 1998, Franklin, Godfrey et al. 2000). Interestingly, a recent study with CKI-impaired mice shows
that INK4 and Cip/Kip inhibitors are necessary for the prevention of replication stress during
development  (Quereda,  Porlan  et  al.  2015).  As  one  would  expect,  the  chromosomal  region  9p21
carrying the INK4a and INK4b genes is frequently altered in many human cancers, underscoring
the importance of CKIs in the anti-tumor activity of the cell (Ruas and Peters 1998).
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3. DNA damage response (DDR)
The DNA of a cell is constantly under stress during each round of replication. DNA damage can
occur by spontaneous alterations such as deamination or depurination that occur during DNA
replication or induced by reactive oxygen species (ROS). Other sources of DNA damage are
environmental inducers such as ionizing radiation (IR), UV, chemical agents such as
chemotherapeutic agents and virus infection.  To secure genomic integrity, the cell is armed with
multiple DNA repair mechanisms specific for the type of DNA damage. For instance, double
stranded breaks (DSB) are repaired with non-homologous end joining (NHEJ) or homologous
recombination (HR), while single stranded breaks (SSB) are repaired with single-strand break repair
(SSBR). The initiation of a repair process and the induction of apoptosis when the damage cannot
be repaired are orchestrated by a series of events known as the DNA damage response (DDR).
DDR involves an intricate signaling network regulating recognition, timing and implementation of
DNA repair,  cell  cycle  arrest  and  apoptosis.  Major  mediators  of  DDR are  phosphatidyl  inositol  3
kinase-like protein kinases (PIKKs), ataxia telangiectasia mutated (ATM), ataxia telangiectasia and
Rad3-related protein (ATR) and DNA-dependent protein kinase (DNA-PK). ATM and DNA-PK
are activated by DSBs while ATR is activated by single stranded DNA (ssDNA) and DSBs (Ciccia
and Elledge 2010). ATM/ATR promote DSB repair by recruiting DDR factors to damaged DNA.
To  achieve  this,  ATM  phosphorylates  the  H2AX  histone  (also  known  as  γH2AX)  at  Ser139  in
nucleosomes, close to the DSB site. Once phosphorylated, γH2AX recruits DDR factors, including
ATM, to the site of DNA damage as well as chromatin modifiers, like SWItch/Sucrose Non-
Fermentable (SWI/SNF), which open the chromatin, giving access to DNA repair proteins (Lee,
Park et al. 2010). Active ATM phosphorylates the checkpoint kinase 2 (Chk2), which
phosphorylates and activates p53. Active p53 can induce DNA repair, cell cycle arrest or apoptosis
by activating the expression of downstream target genes (Riley, Sontag et al. 2008). Additionally,
ATM can phosphorylate the Cdk-activating phosphatase cell Cdc25A and induce its proteolytic
degradation. This inhibits activation of Cdk2 and induces G1 arrest.
If the replication fork stalls during S-phase, the consequent DNA damage will activate ATR, which
phosphorylates and activates the Chk1 kinase. Active Chk1 phosphorylates and causes proteolysis
of Cdc25A, inhibiting Cdk2/cyclin E/A, hence inhibiting DNA replication (Bartek and Lukas
2001). DSBs that occur in G2 phase activate both ATM and ATR, leading to phosphorylation of
Chk-1 and -2 and Cdc25A. This  inhibits Ckd1/cyclin B activation, preventing cells from entering
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M-phase (Bartek and Lukas 2007). This G2/M checkpoint is crucial to avoid the passage of
damaged  DNA  to  one  of  the  dividing  cells.  Inhibition  of  G2/M  arrest  in  the  presence  of  DNA
damage induces apoptosis. As discussed later in this thesis, viruses can take advantage of cell cycle
checkpoints to induce cell cycle arrest and prevent apoptotic mechanisms.
4. Tumor suppressor p53
p53 is a tumor suppressor protein, originally discovered from research on murine cells transformed
by the DNA tumor virus Simian virus 40 (SV40).  It was found that the viral large T-antigen protein
interacted with p53 (Lane and Crawford 1979, Linzer and Levine 1979, Finlay, Hinds et al. 1989).
p53 is a stress sensor protein capable of halting the cell cycle and inducing apoptosis in response to
stress signals such as DNA damage, aberrant expression of oncogenes and hypoxia, making it an
efficient barrier against tumorigenesis (Giaccia and Kastan 1998, Bieging, Mello et al. 2014). p53
functions as a transcription factor, activating the transcription of target genes that regulate
apoptosis, senescence, DNA repair and cell cycle arrest. The TP53 gene is mutated or lost in about
50% of all human cancers (Hollstein, Sidransky et al. 1991, Levine, Momand et al. 1991, Feki and
Irminger-Finger 2004, Bouaoun, Sonkin et al. 2016). Interestingly tumor viruses have developed
multiple mechanisms to inhibit p53 and to promote tumorigenesis (Sato and Tsurumi 2013).
p53 consists of three functional domains that provide sequence-specific DNA binding (DNA
binding domain, DBD), transcriptional activation (TAD domains) and oligomerization
(tetramerization domain, TET) (Beckerman and Prives 2010). The vast majority of tumor-
associated mutations in p53 are missense mutations in the DBD that disrupt the interaction of p53
with DNA and prevent transactivation of target genes (Thukral, Lu et al. 1995, Olivier, Hollstein et
al. 2010). These mutants act in a dominant negative manner (Willis, Jung et al. 2004). Upon stress,
p53 is phosphorylated at multiple sites, stabilized, and forms homo-tetrameric complexes via TET
domain (Friedman, Chen et al. 1993). The p53 tetramers bind to specific p53-response DNA
elements comprising two half-sites of the following consensus nucleotides: RRRCWWGYYY,
where R stands for purine, W stands for A or T and Y stands for pyrimidine. These half-sites are
separated by a  spacer region of  0-13 nucleotides (el-Deiry, Kern et al. 1992).
4.1. The role of p53 in apoptosis
p53 regulates both the intrinsic and extrinsic apoptotic pathways by activating the expression of
pro-apoptotic genes (Haupt, Berger et al. 2003). p53 can induce intrinsic apoptosis by activating the
expression  of  Bax or  BH3-only  proteins  Bid,  PUMA or  PMA-Induced  Protein  (Noxa),  and  cause
the release of cytochrome C from mitochondria as well as activation of caspases (Miyashita,
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Krajewski et al. 1994, Oda, Ohki et al. 2000, Nakano and Vousden 2001, Sax, Fei et al. 2002).
Additionally,  p53  can  activate  the  expression  of  Apaf-1  and  promote  the  formation  of  the
apoptosome in response to stress (Soengas, Alarcon et al. 1999, Robles, Bemmels et al. 2001).
Interestingly, p53 can also induce apoptosis in a transcriptionally independent manner by binding
Bcl-XL and Bcl-2 proteins, leading to permeabilization of the outer mitochondrial membrane
(Mihara, Erster et al. 2003, Chipuk, Kuwana et al. 2004, Tomita, Marchenko et al. 2006, Vaseva
and Moll 2009). p53 can mediate the execution of the extrinsic apoptosis pathway by activating the
expression and increasing the levels of the death receptors Fas and DR5 (Wu, Burns et al. 1997,
Muller, Wilder et al. 1998) and inducing the expression of the death ligands FasL and TNF-related
apoptosis-inducing ligand (TRAIL) (Maecker, Koumenis et al. 2000, Kuribayashi, Krigsfeld et al.
2008).
4.2. The role of p53 in cell cycle arrest
To be able to preserve the integrity of the genome upon DNA damage, p53 can stop the cell cycle at
the  G1 or  G2 phase  to  prevent  replication  of  the  damaged DNA in  S-phase  or  segregation  of  the
damaged chromosomes during mitosis (Giono and Manfredi 2006). p53 can activate the expression
of the p21Cip1 gene cyclin dependent kinase inhibitor 1A (CDKN1A) upon DNA damage (e.g.
caused by reactive oxygen species or radiation) and induce G1 cell cycle arrest (el-Deiry, Tokino et
al. 1993). Furthermore, p53 can induce G2/M cell cycle arrest mainly by activating genes, such as
CDKN1A,  Growth  Arrest  and  DNA  Damage  (GADD45), 14-3-3δ and Reprimo, whose products
inhibit the Cdk1/cyclin B complex. p53 can also repress Cdk1 and cyclin B expression directly
(Taylor and Stark 2001).
4.3. Modulation of p53 activity
A classical p53 response consists of a sequence of events: i) stress-induced stabilization of p53 by
phosphorylation ii) tetramerization and binding of p53 to DNA and iii) target gene activation in
collaboration with other components of the DNA transcription machinery. The activity of p53 is
regulated by multiple different post-transcriptional modifications including phosphorylation,
acetylation and ubiquitination. These modifications have an effect on the stability, transcriptional
function and cellular localization of p53.
Depending on the type of stress or form of DNA damage, certain types of kinases are activated and
phosphorylate p53. For instance, ATM, ATR, DNA-PK, Chk1 and Chk2  kinases phosphorylate
and activate p53 upon DNA damage (Kruse and Gu 2009). These kinases phosphorylate p53 at Ser
15 and Ser 20. These phosphorylation events lead to the stabilization of p53 by disrupting the
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interaction between p53 and its negative regulator, the E3 ubiquitin ligase,  Mdm2 (Shieh, Ikeda et
al. 1997, Shieh, Ahn et al. 2000, Appella and Anderson 2001).
Acetylation of p53 is important for its transactivation function and for the recruitment of  cofactors
(Kruse and Gu 2009). p53 is acetylated mainly by the histone acetyltransferase (HAT) CREB
binding protein (CBP/p300) (Gu and Roeder 1997). During the stress response, the acetylation
levels  of  p53  increase  rapidly  and  this  correlates  with  the  activation  and  stabilization  of  p53  (Ito,
Lai et al. 2001). p53 can be acetylated at multiple different lysine residues, which modulates the
recruitment of different cofactors on target gene promoters, thus regulating the type of p53 response
(Kruse and Gu 2009). For example, K120 acetylation of p53 is required for transactivation of the
pro-apoptotic Bax and Puma genes, but not for p21CIP1 or Mdm2 expression (Tang, Luo et al. 2006,
Mellert, Sykes et al. 2007).
Under normal conditions, p53 is constantly expressed, but its half-life is only 5-20 minutes since it
is continuously ubiquitinated mainly by Mdm2 and degraded by the proteasome. MDM2 gene
expression is, in turn, regulated by p53, thus establishing a negative feedback loop which maintains
low levels of p53 in normal, unstressed cells (Li, Brooks et al. 2003, Chao 2014).
4.4. Regulation of p53 by Mdm2
Mouse double minute-2 gene (MDM2) was firstly found as name denotes from double minute
chromosomes of spontaneously transformed balb/c3T3 mouse cells (Cahilly-Snyder, Yang-Feng et
al. 1987) and later the human homolog was found to be associated with tumor suppressor p53
(Momand,  Zambetti  et  al.  1992).  Mdm2  consists  of  several  domains,  which  are  important  for  its
function. In NH2-termini locates p53 binding domain and in central region locates nuclear
localization sequence (NLS), nuclear export signal (NES) and acidic domain and in COOH-termini
locates RING finger domain carrying E3 ubiquitin ligase activity (Fakharzadeh, Trusko et al. 1991,
Chen, Marechal et al. 1993, Roth, Dobbelstein et al. 1998, Fang, Jensen et al. 2000). Mdm2 can
inhibit p53 function by two means either by binding transactivation domain of p53 and thus
blocking its ability to activate transcription of its target genes or target p53 for proteasomal
degradation (Kussie, Gorina et al. 1996). Depending on Mdm2 levels and stress conditions Mdm2
can either monoubiquitinate or polyubiquitinate p53 in the nucleus. Hence in normal unstressed
conditions when there is a low level of Mdm2 it binds and monoubiquitinates p53 and promotes
nuclear export to keep p53 away from its transcriptional targets. In stressed conditions when there is
a  high  amount  of  Mdm2  it  can  in  collaboration  with  transcriptional  co-activator  p300
polyubiquitinate p53 and induce 26S  proteasome degradation of p53 in the nucleus (Lohrum,
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Woods  et  al.  2001,  Grossman,  Deato  et  al.  2003,  Li,  Brooks  et  al.  2003).  It  has  been  shown that
monoubiquitination will expose COOH-terminal NES sequence of p53 and allow proper nuclear
export and in the cytoplasm where p53 can be further poly-ubiquitinated by other E3 and E4 ligases
like for example ubiquitination factor E4B (UBE4B) and directed to 26S proteasome for
degradation (Geyer, Yu et al. 2000, Nie, Sasaki et al. 2007, Wu, Pomeroy et al. 2011). Alternatively
cytoplasmic monoubiquitinated p53 is transported to mitochondrial membrane where it is
deubiquitinated by herpesvirus-associated ubiquitin-specific protease (HAUSP) and protected from
the degradation and thus promoting apoptosis (Marchenko, Wolff et al. 2007). Indicating
transcription independent function of p53 and underlining the important role of Mdm2 levels in
control of p53 activity.
4.5. Regulation of Mdm2
Mdm2 protein stability and function is regulated by several stress signals such as oncogenic
activation or DNA damage, which activates multiple cellular pathways controlling post-
transcriptional modifications and cellular localization of Mdm2 and thus Mdm2-p53 interaction.
Aberrant mitogenic signaling operated by oncogenes such as Ras and V-Myc Avian
Myelocytomatosis Viral Oncogene Homolog (c-Myc) interfere Mdm2 function and stabilize and
activates p53. This process is conducted by another tumor suppressor protein p14ARF, which is
negative regulator of Mdm2 protein (Palmero, Pantoja et al. 1998, Zindy, Eischen et al. 1998).
p14ARF gene is transcribed from alternate reading frame of INK4A/ARF gene locus expressing in
addition to p14ARF cyclin D dependent inhibitor: p16INK4A (Mao, Merlo et al. 1995). p14ARF
inhibit E3 ubiquitin ligase  activity of Mdm2 (Pomerantz, Schreiber-Agus et al. 1998, Honda and
Yasuda 1999). And it has been shown that p14ARF is nucleolar protein is binding central domain of
Mdm2 and sequester Mdm2 to nucleolus thus stabilizing nucleoplasmic p53 (Weber,  Taylor et  al.
1999, Weber, Kuo et al. 2000).
Another important regulator of Mdm2 and p53 is MdmX or also known as Mdm4 protein which is a
homologue of Mdm2 and negative regulator of p53. However MdmX lacks E3 ubiquitin ligase
activity towards p53 it can inhibit p53 function by preventing its transcriptional activity (Toledo,
Krummel et al. 2006). MdmX can regulate protein stability and activity of Mdm2 by forming
hetorodimers with Mdm2 via their RING finger domains and stabilize Mdm2 by preventing auto-
ubiquitination and enhancing its E3 ligase activity towards p53 (Linares, Hengstermann et al. 2003,
Wang, Wang et al. 2011).
REVIEW OF LITERATURE
16
5. Kaposi’s sarcoma herpesvirus (KSHV)
Kaposi’s sarcoma herpesvirus (KSHV or HHV-8) is a human gamma2-herpesvirus and the
causative agent of three human cancers: Kaposi’s sarcoma (KS) and two lymphoproliferative
malignancies: primary effusion lymphoma (PEL) and multicentric Castleman’s disease (MCD).
5.1. Discovery of KSHV and its associated malignancies
Kaposi’s sarcoma (KS) was originally identified by the Hungarian dermatologist Moritz Kaposi in
1872 (Kaposi 1872). During the AIDS epidemic in the early 1980s, KS cases increased dramatically
and the correlation between AIDS and KS led to the hypothesis that another infectious agent would
be involved in the development of KS (Beral, Peterman et al. 1990). Finally, in 1994, Moore and
Chang were able to extract and identify KSHV DNA sequences from KS lesions of AIDS patients
(Chang, Cesarman et al. 1994) A year later Cesarman et al also found KSHV DNA sequences from
AIDS  patients  suffering  from  body  cavity-based  lymphoma  (BCBL,  also  known  as  PEL)
(Cesarman, Chang et al. 1995) and established the BCBL-1 cell line stably infected with KSHV.
This cell line has become an instrumental tool for the further development of the KSHV research
field  (Cesarman,  Moore  et  al.  1995,  Arvanitakis,  Mesri  et  al.  1996).  Around the  same time when
causality between KSHV and PEL was found, another lymphoproliferative disorder, plasmablastic
variant  of  MCD,  was  found  to  be  associated  with  KSHV  infection  (Soulier,  Grollet  et  al.  1995,
Gessain, Sudaka et al. 1996).
5.1.1. Kaposi’s sarcoma
KS usually appears as highly angiogenic lesions on the skin of the upper and lower body extremities
or on mucosal surfaces. Visceral organs and lymph nodes can also harbor these lesions.
Histologically, KS lesions consist of spindle-shaped tumor cells, with a high number of
disorganized and leaky blood vessels and extravasated red blood cells causing the purple, red or
brown coloration of the lesion (Antman  and Chang 2000, Orenstein 2008). KS lesions are not like
typical tumor tissues arising from outgrowth of a clonal cell  population. They instead consist  of a
wide variety of different cell types such as endothelial cells, macrophages and smooth muscle cells
(Weich, Salahuddin et al. 1991, Kaaya, Parravicini et al. 1995, Sturzl, Brandstetter et al. 1995,
Dupin, Fisher et al. 1999). Although KS spindle cells have been identified to be of endothelial
origin and express multiple blood endothelial markers (like CD31 and CD34) it has been reported
that these cells can also express lymphatic endothelial markers like vascular growth factor receptor
3  (VEGFR3)  and Lymphatic Vessel Endothelial Hyaluronan Receptor 1 (LYVE-1) (Browning,
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Sechler et al. 1994, Weninger, Partanen et al. 1999, Hong, Foreman et al. 2004, Wang, Trotter et al.
2004).
KS lesions progress through different stages. In the early stage, also called the patch and plaque
stage, lesions appear small and flat. In the later, nodular stage, lesions grow further in thickness and
they contain highly proliferating spindle cell layers and slit-like neovascular spaces (Ganem 2010).
Over 95% of KS lesions contain KSHV DNA (Dupin, Fisher et al. 1999). There are four forms of
KS: Classic KS, Endemic KS, Iatrogenic/post-transplant KS and AIDS-associated/Epidemic KS.
The classic KS is usually an indolent and chronic disease affecting elderly men of Mediterranean
and eastern European Jewish ancestry (Oettle 1962). Endemic KS mainly affects young populations
of sub-Saharan Africa, where it is one of the most common cancers. Endemic KS is not associated
with human immunodeficiency virus (HIV) infection, but it is more aggressive than classic KS
(Taylor, Templeton et al. 1971, Bayley 1984). The Iatrogenic KS affects patients treated with
immunosuppressive therapy after organ transplantation (Andreoni, Goletti et al. 2001, Marcelin,
Calvez et al. 2007). The AIDS-associated KS, also called epidemic KS, is the most common and
most aggressive form of KS affecting HIV-positive individuals, and it has been identified as an
AIDS-defining disease (Giffin and Damania 2014). Recent epidemiological studies indicates that
although  combination  antiretroviral  treatment  (cART)  is  able  to  control  HIV-1  replication  and
restore CD4+ T-cell counts of HIV positive individuals and thus KS incidences have been
significantly declined, KS is the most common cancer in HIV infected individuals and is the most
prevalent cancers in Africa (Casper 2011, Rohner, Valeri et al. 2014, Labo, Miley et al. 2015).
5.1.2. Primary effusion lymphoma
Primary effusion lymphoma (PEL) is a non-Hodgkin’s lymphoma (NHL) consisting of monoclonal
B-type cells that expand in body cavities such as the pleural space, pericardium and peritoneum.
There are also some solid PEL cases, where the tumors usually appear extra-nodaly (Carbone,
Gloghini et al. 2005). Each tumor cell has about 30-100 copies of the KSHV genome (Renne,
Lagunoff et al. 1996). Clonal immunoglobulin gene rearrangements and somatic hypermutations
have been observed in PEL cells, indicating that these cells originate from the post-germinal center
B-cells (Matolcsy, Nador et al. 1998). PEL is not a typical lymphoma, since it lacks c-myc gene
rearrangements, Bcl-2, Ras and, in most cases, TP53 gene alterations (Cesarman and Knowles
1999). PEL cells lack expression of B- and T-cell associated antigens but they express the CD45
antigen, which is a marker of haematolymphoid cells. Additionally PEL cells express various
markers of lymphocyte activation such as CD30, CD38, CD71 and several plasma cell markers
including CD138, VS38c and MUM1/IRF4 (Cesarman and Knowles 1999, Carbone, Gloghini et al.
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2001).  All  of this indicates that  PEL cells partially resemble differentiated plasma cells.  PEL is a
rare disease,  being present in only 4% of HIV-associated NHL cases and 0,4 % of HIV-unrelated
NHLs (Carbone, Gloghini et al. 1996). PEL cases are rarely found in HIV-negative patients who
have received a solid organ transplant or in elderly men of Mediterranean descent (Jones, Ballestas
et al. 1998, Dotti, Fiocchi et al. 1999, Klepfish, Sarid et al. 2001). PEL has a poor prognosis and the
median survival time after diagnosis is only 6 months (Boulanger, Gerard et al. 2005). Prognosis of
PEL in HIV-infected individuals is dependent on highly active antiretroviral therapy (HAART) and
performance  status  prior  to  PEL diagnosis  (Simonelli,  Spina  et  al.  2003,  Boulanger,  Gerard  et  al.
2005). Additionally, KSHV viral load might be a prognostic factor for the outcome of PEL disease
(Simonelli, Tedeschi et al. 2006). Currently there is no effective therapy for PEL and conventional
chemotherapy is not curative. Therefore, novel therapeutic approaches are needed.
5.1.3. Other KSHV associated diseases
KSHV is associated with a plasmablastic variant of multicentric Castleman’s disease (MCD)
(Soulier, Grollet et al. 1995). MCD is a rare neoplastic lymphoproliferative disorder comprising
highly proliferating IgM λ-restricted plasmablasts in the mantle zone of the germinal center (Du,
Liu  et  al.  2001).  Almost  all  HIV-positive  MCD  patients  are  co-infected  with  KSHV  and  40%  of
HIV-negative MCD patients are KSHV-positive. MCD patients who are co-infected with HIV and
KSHV have a more aggressive disease with poorer prognosis and they frequently have other
malignancies, including KS and PEL (Soulier, Grollet et al. 1995). MCD patients have systemic
lymphadenopathy and inflammatory manifestation and disease progression is caused by
dysregulated IL-6, IL-10 and vascular growth factor (VEGF) cytokine production. KSHV can
further promote the progression of MCD by expressing viral IL-6 (vIL6), which can increase the
expression of human IL-6 and VEGF (Giffin and Damania 2014). High viral loads of KSHV and
high levels of vIL6 expression have been linked to rapid progression of the disease (Parravicini,
Corbellino et al. 1997, Oksenhendler, Carcelain et al. 2000).
KSHV infection is also linked to a more recently identified disease called KSHV-associated
inflammatory cytokine syndrome (KICS). In this syndrome patients have MCD-like inflammatory
symptoms, but without lymphadenopathy. KICS patients have elevated cytokine levels of IL-6, IL-
10, C-reactive protein and vIL6 (Uldrick, Wang et al. 2010). These patients have high KSHV viral
loads, indicating a high rate of lytic KSHV infection (Polizzotto, Uldrick et al. 2012).
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5.2. KSHV biology
5.2.1. Taxonomy
KSHV belongs to the large herpesviridae family of double-stranded DNA viruses. The currently
known eight human herpesviruses (HHV) can be categorized into three subgroups: α-, β- and γ-
herpesviruses. Herpes simplex-1 and 2 and varicella zoster (VZV or HHV-3) viruses belong to the
α-herpesvirus group. The β-herpesvirus group comprises cytomegalovirus (CMV or HHV-5), HHV-
6 and 7 viruses. The γ-herpesvirus group is divided into two subgroups: γ-1lymphocryptoviruses,
including Epstein-Barr virus (EBV or HHV-4), and γ-2 rhadinoviruses, including KSHV or HHV-8
(Giffin and Damania 2014). EBV infection causes mononucleosis, and like KSHV, it is the
causative agent of several human cancers in immunocompromised individuals (Cesarman 2011).
5.2.2. Viral transmission and infection rates
KSHV can be transmitted via saliva, and in endemic countries, mother-to-child transmission is
fairly common (Moore 2000). Additionally, KSHV can be transmitted via sexual contact or blood
transfusions  (Martin,  Ganem  et  al.  1998,  Hladik,  Dollard  et  al.  2006).  There  is  a  high  global
variation in seroprevalence of KSHV, since in the endemic areas, such as in Africa, seroprevalence
is as high as over 50 %, and in Southern Europe it varies between 10-30 %, whereas in Northern
Europe and in the United States it is only 1-6 % (Gao, Kingsley et al. 1996, Kedes, Operskalski et
al. 1996, Simpson, Schulz et al. 1996, Schatz, Monini et al. 2001). Usually KSHV DNA genomes
are detected in peripheral B-cells, but also in T-cells, endothelial cells, epithelial cells and even
monocytes (Ambroziak, Blackbourn et al. 1995, Blasig, Zietz et al. 1997, Dupin, Fisher et al. 1999,
Henry, Uthman et al. 1999, Pauk, Huang et al. 2000).
5.2.3. Virion structure and viral entry
KSHV virion consists of lipid bilayer envelope, tegument, icosahedral capsid structures and linear
double stranded DNA genome (Figure 3A). Transmembrane glycoproteins of the virion envelope
mediate attachment and entry of the KSHV virion via fusion or endocytosis into target cell (Akula,
Pramod et al. 2001, Pertel 2002). KSHV glycoproteins K8.1A and gB bind heparin sulfate of the
target cell and mediate attachment of the virion to the target cell membrane (Akula, Pramod et al.
2001, Birkmann, Mahr et al. 2001, Wang, Akula et al. 2001). KSHV virion entry occurs via
interaction between viral glycoproteins and target cell surface receptors and currently it is known
that integrins α3β1, αVβ3 and αVβ5 and 12-transmembrane transporter protein xCT plays a role in
this process (Akula, Pramod et al. 2002, Wang, Akula et al. 2003, Kaleeba and Berger 2006,
Garrigues, Rubinchikova et al. 2008). KSHV virion enters the cell via clathrin mediated endocytosis
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or micropinocytosis (Akula, Naranatt et al. 2003, Raghu, Sharma-Walia et al. 2009). Tegument
layer of the virion exists between the envelope and capsid and it  consist  of viral  proteins such as
open reading frames (ORFs) 45 and 64 and 11 viral RNA transcripts (Bechtel, Grundhoff et al.
2005, Bechtel, Winant et al. 2005). Icosahedral KSHV capsid forms a shell which is composed of
capsomers and capsid floor compartments which are composed of major capsid proteins ORF25,
ORF62, ORF26, ORF17.5 and minor capsid protein ORF65 (Wu, Lo et al. 2000, Nealon, Newcomb
et al. 2001). KSHV genome is linear double stranded DNA surrounded by capsid. Genome consist
of 140 kb long coding sequence flanked by terminal repeat (TR) regions (Renne, Lagunoff et al.
1996). KSHV genome encodes 87 ORFs and also mRNA and other non-coding RNAs (Figure 3B)
(Russo, Bohenzky et  al.  1996, Samols,  Hu et  al.  2005).  One of the striking features of the KSHV
genome  is  that  it  contains  a  high  number  of  ORFs  which  are  human  orthologues  which  play  an
important role in tumorigenesis.
Figure 3. Structure of KSHV virion and genome. A) KSHV virion consists of lipid bilayer envelope, tegument,
icosahedral capsid structures and linear double stranded DNA genome. B) KSHV genome consist of 140 kb long coding
sequence flanked by terminal repeat (TR) regions KSHV genome encodes 87 ORFs and also microRNAs (miRNA
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cluster). During latency, KSHV expresses only a small number of its genes and miRNAs (Latency locus, green arrows),
whereas during lytic replication all lytic genes are expressed (red arrows).
5.2.4. KSHV life cycle
KSHV establishes persistent life-long infection and manipulates host cell proliferation,
differentiation, metabolism, apoptosis and immunity (Mesri, Cesarman et al. 2010). KSHV has two
life cycle phases: the latent phase and the lytic replication phase. Latency is a silent mode of
infection whereby KSHV hides its DNA genome inside the host cell nucleus, only synthesizing a
few proteins and miRNAs, thus avoiding detection by the immune system. In the lytic replication
phase, new viral progeny are produced, ultimately leading to the lysis of the host cell. Latency is the
default infection mode for KSHV (Zhong, Wang et al. 1996). Physiological factors like hypoxia,
oxidative  stress,  and  inflammatory  cytokines  or  chemicals  such  as  the  protein  kinase  C  (PKC)
antagonist 12-O-tetradecanoylphorbol-13-acetate (TPA), or HDAC inhibitors such as sodium
butyrate (NaB) can reactivate the virus from its latent phase and initiate the lytic replication phase
(Yu, Black et al. 1999, Davis, Rinderknecht et al. 2001, Pantry and Medveczky 2009, Ye, Zhou et
al. 2011).
5.2.5. Establishment of latent infection
Upon entry into its target cell, KSHV activates the PI3K signaling pathway-activating Rho GTPases
to alter the actin cytoskeleton and aid in the delivery of the capsid into the cytoplasm of the infected
cell (Sharma-Walia, Naranatt et al. 2004, Greene and Gao 2009). The nucleocapsids travel to the
nucleus and after uncoating, release the viral genome (Naranatt, Akula et al. 2003, Naranatt,
Krishnan et al. 2005). The released linear genome is circularized and associates with cellular
histones (i.e. it becomes 'chromatinized') forming a tightly packed viral episome. The
chromatinization process protects the episome from DNA damage and enables transcriptional
regulation of viral gene expression (Lieberman 2013). In this state, the viral episome is then
tethered to chromosomes of the host cell (extrachromosomal episome) to ensure its maintenance
during cell divisions (Ballestas, Chatis et al. 1999).
During latency, KSHV expresses only a small number of its genes (Table 1): the Latency
Associated Nuclear Antigen (LANA and LANA2 also called viral interferon regulator factor 3
(vIRF3)), viral cyclin (v-cyclin), viral FLIP (vFLIP), Kaposin A and B (Fakhari and Dittmer 2002).
KSHV  genome  carries  also  viral  miRNAs.  miRNAs  are  short  non-coding  RNAs  (20-24
nucleotides) that modulate gene expression by binding 3´Untranslated region (3’UTR) of the target
gene. 5’end of the miRNA carry 2-8 nucleotides long seed sequence which determines the target for
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the miRNA (Bartel 2009). KSHV encodes 12 pre-miRNAs which are located in the latency locus.
Ten of these miRNAs (miR-K12-1 to miR-K12-9 and miR-K12-11) are located in the intron of the
K12 gene and two of them (miR-K12-10 and miR-K12-12) are located in the coding region of K12
gene (Figure 3B) (Zhu, Haecker et al. 2013). Many of the KSHV miRNAs have been reported to
target cellular genes regulating proliferation, cell survival and apoptosis (Haecker, Gay et al. 2012,
Zhu, Haecker et al. 2013). During latency, the KSHV genome is replicated by the host DNA
replication machinery along with cellular DNA once every cell division. After mitosis, duplicated
viral genomes are segregated amongst daughter cells, but no viral progeny are produced (Cotter and
Robertson 1999, Barbera, Chodaparambil et al. 2006, You, Srinivasan et al. 2006, Matsumura,
Persson et al. 2010). Establishment and maintenance of latent infection is inefficient in vitro, since
cells extracted from KS lesions or de novo-infected cell lines tend to lose their KSHV genome upon
cell culturing (Dictor, Rambech et al. 1996, Lagunoff, Bechtel et al. 2002). Only exceptionally do
cell lines extracted from PEL patients carry KSHV genomes stably in culture (Cesarman, Moore et
al. 1995).
LANA is the hallmark of KSHV latent infection. LANA can be visualized with indirect
immunofluorescence staining as a speckled nuclear pattern (Gao, Kingsley et al. 1996). Nearly all
cells in KS lesions express LANA (Dittmer, Lagunoff et al. 1998) and LANA protein is detected in
all KSHV-associated malignant cells (Dupin, Fisher et al. 1999). LANA is encoded by the ORF73
gene (Kedes, Lagunoff et al. 1997, Kellam, Boshoff et al. 1997, Rainbow, Platt et al. 1997) and is
transcribed from the polycistronic latency transcript locus together with v-cyclin (ORF72) and v-
FLIP (ORF71) (Dittmer, Lagunoff et al. 1998). LANA’s most important functions are to establish
and maintain stable latent infection by ensuring replication and segregation of the KSHV genome
during cell division and to circularize the KSHV genome by binding terminal repeat (TR) regions
(Ballestas, Chatis et al. 1999, Ballestas and Kaye 2001).
5.2.6. Reactivation from latency and the lytic cycle
The term, “reactivation” refers to the induction of the lytic replication phase, which can be triggered
by a variety of stresses. Transcription of the viral lytic genes is activated in a carefully orchestrated
cascade. The first viral lytic gene synthesized upon reactivation is the Replication and Transcription
Activator (RTA). RTA is encoded by the gene, ORF50, and is necessary and sufficient to disrupt
latency and initiate a full lytic cascade (Lukac, Renne et al. 1998, Sun, Lin et al. 1998). RTA is a
transcription factor responsible for the transactivation of the downstream lytic genes and auto-
activation of its own promoter (Guito and Lukac 2012). During the lytic cycle, viral genes are
expressed in a temporally regulated order with immediate early (IE) genes expressed first, followed
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by expression of delayed-early (DE) genes that trigger lytic DNA replication, followed by the
expression of late (L) genes that encode the  structural proteins of the virion (Sun, Lin et al. 1999).
RTA can activate the expression of multiple DE genes directly or indirectly, such as K2 encoding
viral interleukin-6 (vIL-6), polyadenylated nuclear RNA (PAN), ORF57 encoding mRNA transport
and accumulation protein (MTA), K8 encoding replication-associated protein (RAP), ORF74
encoding viral G protein-coupled receptor (vGPCR) and many others (Table 1) (Purushothaman,
Uppal et al. 2015). The RTA responsive elements, RRE, mediate direct binding to the respective
promoters (Song, Deng et al. 2003). RTA can also mediate gene expression indirectly by interacting
with cellular transcription factors (Figure 4) (Liang, Chang et al. 2002, Song, Deng et al. 2003,
Wang, Wu et al. 2003) such as the Notch signaling mediator Recombining binding protein
suppressor of hairless (RBP-Jκ). Interestingly, virus reactivation was inhibited in KSHV-infected
RBP-Jκ-null murine fibroblasts, underscoring the important role of RBP-Jκ for reactivation in vivo
(Liang  and  Ganem  2003).  Additionally,  RTA  interacts  with  other  cellular  TFs  such  as  AP-1,  a
heterodimeric transcription factor complex consisting of proteins belonging to the c-Jun and c-Fos
families  (Hess,  Angel  et  al.  2004)  that  co-operate  with  RTA and activate  the  expression  of  some
lytic genes, (Byun, Gwack et al. 2002, Wang, Wu et al. 2004) thereby promoting the lytic gene
expression cascade (Wang, Wu et al. 2003). Also, the X-box binding protein (XBP-1) has been
shown to transactivate ORF50 and induce reactivation of PEL cells (Wilson, Tsao et al. 2007, Yu,
Feng  et  al.  2007).   In  addition  to  cellular  TFs,  RTA  activity  requires  the  recruitment  of
transcriptional co-factors like the histone acetyl transferase CREB binding protein (CBP), the
chromatin remodeling complex SWI/SNF and the co-activator TRAP/mediator (Figure 4) (Gwack,
Baek et al. 2003).
The activity of RTA can also be repressed by some cellular proteins. Interferon regulatory factor
(IRF)-7 can repress RTA-mediated transactivation by competing with RTA for ORF57 promoter
binding (Wang, Zhang et al. 2005). As a countermeasure, RTA has E3 ubiquitin ligase activity
against IRF-7 which targets the cellular proteins for proteasomal degradation, thereby counteracting
host defense mechanisms and ensuring viral reactivation (Yu, Wang et al. 2005).
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Table 1. Classification of KSHV genes
Gene and gene description Life cycle phase
ORF73/LANA (Latency-Associated Nuclear Antigen) Latent
K10.5/LANA2/vIRF3 (viral interferon regulatory factor 3) Latent
ORF72/v-cyclin (viral homolog of human cyclin D2 Latent
ORF71/vFLIP (viral FLIP) Latent
K12/Kaposin Latent
miRNA cluster (12 viral pre-miRNAs) Latent
ORF50/RTA (Replication and Transcription Activator) Lytic (IE)
PAN (polyadenylated nuclear RNA) Lytic (DE)
ORF57/MTA (mRNA transport and accumulation protein) Lytic (DE)
K8/RAP/K-bZIP (replication-associated protein, transcription
factor)
Lytic (DE)
ORF74/vGPCR (viral G protein-coupled receptor Lytic (DE)
K2/vIL6 (viral interleukin-6) Lytic (DE)
K9/vIRF1 (viral interferon regulatory factor 1) Lytic (DE)
K10/vIRF4 (viral interferon regulatory factor 4) Lytic (DE)
ORF16/vBcl2 (viral Bcl-2) Lytic (DE)
K7/vIAP (anti-apoptotic protein) Lytic (DE)
ORF22 (glycoprotein) Lytic (L)
ORF17.5 (major capsid protein) Lytic (L)
ORF25 (major capsid protein) Lytic (L)
ORF26 (major capsid protein) Lytic (L)
ORF62 (major capsid protein) Lytic (L)
ORF 65 (minor capsid protein) Lytic (L)
ORF45 (tegument protein) Lytic (L)
ORF64 (tegument protein) Lytic (L)
K8.1A (glycoprotein) Lytic (L)
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5.2.7. Regulation of reactivation
5.2.7.1. Chromatin modifications controlling the KSHV life cycle
Chromatin  consists  of  DNA  wrapped  around  histone  proteins  (H2A,  H2B,  H3  and  H4)  that
associate together forming an octameric complex: the nucleosome. The structure of chromatin, i.e.
the degree of condensation of DNA and nucleosomes, can be modulated by post-translational
modification of the N-terminal tails of the core histones. These structural changes determine
whether or not the double helix can be accessed by transcription or DNA replication factors i.e. low
(euchromatin) or high condensation (heterochromatin), respectively (Bannister and Kouzarides
2011). Histones can be acetylated, methylated, phosphorylated or ubiquitinated and these
modifications affect chromatin condensation. Histone modifying enzymes such as HATs, HDACs,
histone methyl transferases (HMTs) and histone demethylases are among the enzymes that perform
post-translational modifications of the histones. Modified histones serve as platforms for the
recruitment of both activators and repressors of transcription. Thus, histone modifying enzymes
affect gene expression (Bannister and Kouzarides 2011). Similar to cellular nucleosomes, the
histones in the chromatinized KSHV episome are also modified to regulate transcription of viral
genes and thus the viral life cycle (Figure 4).
During latency, the promoters of latent genes are associated with histones that have activating
modifications such as H3K27me3 (Gunther and Grundhoff 2010, Toth, Maglinte et al. 2010), while
the early lytic genes ORF50 (RTA) and ORF48 have bivalent histone modifications, including both
repressive marks (H3K27me3) and active marks (H3K4me3). Conceivably, the balance between
these modifications determines the transcriptional state of these genes and allows viral gene
expression to switch from latent to lytic. As mentioned earlier, the KSHV-infected cells are mostly
in the latent phase. Thus, during this phase, the promoters of the late lytic genes contain repressive
chromatin marks (e.g. H3K27me3 and H3K9me3), providing the transcriptional control needed to
maintain latency.
Upon reactivation of lytic genes, the levels of active histone marks, such as AcH3 and H3K4me3,
increase, while those of repressive modifications, e.g. H3K27me3, decrease. This results in the up-
regulation of viral lytic gene transcription (Toth, Maglinte et al. 2010). Similarly, histone
methyltransferase enzymes belonging to the Polycomb repressive complex 2 (PRC2) EZH2, which
are responsible for the repressive H3K27me3 marks during latency, dissociate from the reactivated
KSHV  genome,  favoring  activation  of  IE  and  DE  gene  promoters  (Figure  4).  This  de-repression
mechanism is crucial for the maintenance of latency, as inhibition of EZH2 leads to expression of
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lytic genes even during latency in latent PEL cells,  showing that the PRC2 complex is repressing
expression of lytic genes in latency (Toth, Maglinte et al. 2010). Furthermore, overexpression of
demethylases of H3K27me3, Ubiquitously transcribed tetratricopeptide repeat gene on X
chromosome (UTX) and Jumonji domain containing-3 (JMJD3) cause induction of lytic gene
expression in the latent cells (Gunther and Grundhoff 2010, Toth, Maglinte et al. 2010). It has been
shown that demethylases UTX and JMJD3, and H3K4me3 histone methyltransferase histone-lysine
N-methyltransferase 2 (MLL2) are recruited to the ORF50 promoter  by  PAN  RNA  to  activate
expression of IE genes (Figure 4) (Rossetto and Pari 2012). This could suggest a PAN RNA-driven
positive feedback mechanism to boost expression of RTA and other IE genes in the late lytic
reactivation phase. More recently, it has been reported that during latency, the RTA promoter is
repressed by the transcriptional repressors Hey1 and mSin3a. Upon reactivation, the E3 ubiquitin
ligase activity of RTA targets these cellular proteins for degradation, making the reactivation
process more efficient (Gould, Harrison et al. 2009).
Figure 4. Regulation of KSHV reactivation. During latency transcription of lytic genes is repressed by HDAC and by
histone methyltransferase enzymes belonging to the PRC2 complex. Physiological factors such as hypoxia, ROS or
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chemicals like TPA, HDAC inhibitors can reactivate latent infection. Upon reactivation the levels of active histone
marks, such as acetylated histone H3 (AcH3) and trimethylated histone 3 at lysine 4 (H3K4me3) increase. Histone
demethylases UTX and JMJD3 and MLL and transcriptional co-factors like the histone acetyl transferase CBP and the
chromatin remodeling complex SWI/SNF open the viral chromatin. KSHV replication and transcription activator
(RTA/ORF50) activates transcription of lytic genes directly and in co-operation with transcription factors XBP-1, AP-1)
and RBP-Jκ. Lytic reactivation leads to production of new viral progeny and ultimately leading to the lysis of the host
cell.
5.2.7.2. Chemical induction
The KSHV lytic cycle can be artificially induced by several chemicals. These include the PKC
agonist, 12-O-tetradecanoyl-phorbol-13-acetate (TPA), pan inhibitors of HDACs such as NaB and
inhibitors of DNA-methyl transferase (DNMTs). Chemical induction can significantly enhance
reactivation in cell culture systems, offering a valuable tool to study the mechanisms of lytic
replication in vitro.
5.2.7.2.1. Phorbol ester TPA
TPA is a protein kinase C agonist (Niedel, Kuhn et al. 1983), and induces the full lytic cycle of
KSHV in a PKC-delta-dependent manner (Renne, Zhong et al. 1996). Importantly, TPA-induced
reactivation can be enhanced by pre-synchronizing cells in the S-phase (McAllister, Hansen et al.
2005). TPA also activates JNK, a kinase that phosphorylates and activates the DNA binding domain
of the transcription factor c-Jun (Engedal, Korkmaz et al. 2002, Yamasaki, Takahashi et al. 2009). It
has also been shown that TPA enhances the binding of AP-1 to the ORF50 promoter and increases
the  phosphorylation  and  activation  of  c-Jun  (Wang,  Wu  et  al.  2004).  These  are  among  the  few
characterized mechanisms that could explain how TPA treatments trigger KSHV reactivation.
5.2.7.2.2. HDAC inhibitors
The most commonly used HDAC inhibitor to study KSHV reactivation and the lytic cycle is NaB,
which is a broad-spectrum class I HDAC inhibitor (Candido, Reeves et al. 1978). NaB treatment
induces  expression  of  RTA,  leading  to  the  full  activation  of  the  lytic  cycle  (Miller,  Heston  et  al.
1997, Yu, Black et al. 1999). As one would expect, during latency, the promoter of ORF50 is
associated  with  several  HDACs  (HDAC  1,  5  and  7)  that  keep  it  repressed.  By  increasing  the
acetylation levels of the core histones H3 and H4, NaB induces the de-repression of ORF50 (Lu,
Zhou et al. 2003, Toth, Maglinte et al. 2010). This is also accompanied by the recruitment of several
transcription factors that bind to 'open' chromatin, such as Sp1, CBP HAT and the chromatin
remodeling complex SWI/SNF (Lu, Zhou et  al.  2003, Ye, Shedd et  al.  2005).  To reveal which of
the HDACs are regulating the lytic cycle, researchers in Lucak's lab tested several class I and II
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HDAC inhibitors, including NaB, valproic acid (VPA) and trichostatin A (TSA) (Shin, DeCotiis et
al.  2014).  This  study  revealed  that  VPA,  which  is  a  class  I  and  II  HDAC inhibitor,  was  the  most
potent inducer of reactivation. On the contrary, overexpression of HDAC 1, 3 and 6 inhibited
reactivation of PEL cells even in the presence of TPA (Shin, DeCotiis et al. 2014), indicating that
histone modifications are downstream of TPA signaling and that they are crucial for the regulation
of KSHV reactivation. Moreover, a recent report shows that the class III HDAC inhibitors
nicotinamide  (NAM) and  sirtinol  could  also  induce  reactivation  of  latent  PEL cells  (Li,  He  et  al.
2014). Similarly to NaB, these HDAC inhibitors also change the chromatin landscape of the ORF50
promoter from the inhibited to active state (Li, He et al. 2014).
5.2.7.3. Natural inducers of reactivation
5.2.7.3.1. Hypoxia
Cells respond to low oxygen levels, i.e. hypoxia, by upregulating the hypoxia-inducible factor
(HIF), a transcription factor that binds and activates the hypoxia response element (HRE) on the
promoter of target genes (Wang, Jiang et al. 1995). It has been shown that KSHV infection induces
HIF1α and HIF2α expression in endothelial cells (Carroll, Bu et al. 2006). Furthermore, hypoxic
cell culture conditions induce reactivation of PEL cells (Davis, Rinderknecht et al. 2001). Analysis
of the ORF50 promoter revealed that it contains a DNA sequence similar to a HRE (Haque, Davis
et al. 2003). Interestingly, it has been shown that LANA, a latent protein that normally prevents
reactivation, interacts with HIF1α in the hypoxic PEL cells and enhances HIF1α-induced expression
of  RTA (Cai,  Lan  et  al.  2006).  Recent  studies  have  identified  HREs in  promoters  of  both  LANA
and RTA, and demonstrated that HIF1α and HIF2α induce LANA expression (Veeranna, Haque et
al.  2012).  This  study  revealed  that  RTA  interacts  with  HIF1α in  the  hypoxic  PEL  cells,  and  that
hypoxia induced RTA-mediated induction of LANA expression (Veeranna, Haque et al. 2012).
These studies suggest the existence of a complex positive-feedback loop whereby hypoxia induces
the expression of LANA and RTA, which in turn enhance their own expression and control
reactivation. In addition to HIF1α, it has also been shown that hypoxia activates XBP-1, which
upregulates the expression of ORF50 and induces reactivation (Dalton-Griffin, Wilson et al. 2009).
Finally, the role of hypoxia in virus reactivation was confirmed by recent studies showing that
genetic depletion of the hypoxia-sensitive transcriptional repressor KRAB-associated protein-1
(KAP1) leads to increased reactivation. It was shown that in hypoxic conditions, KAP1 dissociates
from the KSHV genome, which is otherwise repressed by KAP1 and other stress sensitive
repressors (Zhang, Zhu et al. 2014). Overall these studies show that hypoxia activates binding of
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several RTA coactivators to the ORF50 promoter and induces RTA expression followed by
reactivation.
5.2.7.3.2. Oxidative stress
As a byproduct of cell metabolism or environmental stress, ROS can rapidly accumulate inside cells
and at high enough levels their free radicals can cause severe cellular damage, which results in a
stress response called the oxidative stress response. Oxidative stress has been associated with the
development of many diseases such as diabetes and cancer. Cells cope with ROS by activating the
NF-κB  or  MAPK  pathways  that  lead  to  the  upregulation  of  antioxidants  (Lushchak  2014).  It  has
been shown that hydrogen peroxide (H2O2), a source of ROS, induces reactivation (Li, Feng et al.
2011, Ye, Zhou et al. 2011). H2O2 treatments induce all three MAPK pathways (ERK1/2, JNK and
p38), which eventually activate the transcription factor c-Jun. Inhibition of MAPK pathways blocks
H2O2-induced reactivation, indicating that this process is MAPK pathway-dependent (Ye, Zhou et
al. 2011). Furthermore, the antioxidant N-acetyl cysteine (NAC) inhibited reactivation of PEL cells
(Ye, Zhou et al. 2011). Inhibition of NF-κB increased H2O2 levels and induced lytic gene expression
(Ye, Zhou et al. 2011).
5.3. Modulation of apoptosis and cell cycle in latency
KSHV has evolved multiple mechanisms to escape from the host cell antiviral defense system and
establish a life-long latent infection. Promoting cell division and preventing apoptosis ensures virus
propagation inside the infected cells. Viral proteins expressed during latency modulate cell cycle
regulators, tumor suppressors and cell death regulators and executors to elude from normal cellular
stress responses and regulation (Schulz and Cesarman 2015).
A good example of this is that KSHV-associated tumors infrequently carry p53 mutations and yet
there is not much apoptosis detected from KS tumor sections or PEL cells (Katano, Sato et al.
2001). KSHV can disarm the function of p53 with the help of LANA, which binds both p53 and
MDM2 (Sarek, Kurki et al. 2007, Chen, Hilton et al. 2010), thereby inhibiting its transcriptional
activity and thus preventing p53-mediated cell cycle arrest and apoptosis (Friborg, Kong et al.
1999). Furthermore, overexpression studies have shown that LANA suppresses p53 activity,
increases proliferation and induces genomic instability (Si and Robertson 2006). Additionally,
LANA can manipulate the host's cell cycle and promote proliferation by interacting with cellular
regulatory proteins such as pRb (Radkov, Kellam et al. 2000).
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Another viral protein capable of promoting cell cycle progression during latent infection is a viral
homolog of human cyclin D2 (v-cyclin (ORF72)). V-cyclin shares sequence similarity with human
cyclin D2 and it can form a complex with multiple CDKs, but it almost exclusively binds CDK6
and forms an active holoenzyme with it (Li, Lee et al. 1997). V-cyclin/CDK6 has broader spectrum
of substrates than cellular cyclin D/CDK6 complex since it can phosphorylate substrates including
Rb, histone H1, p27Kip1, p21Cip1,  Bcl-2  and  Nucleophosmin  (NPM)  (Godden-Kent,  Talbot  et  al.
1997, Li, Lee et al. 1997, Mann, Child et al. 1999, Ojala, Yamamoto et al. 2000, Jarviluoma, Child
et al. 2006, Cuomo, Knebel et al. 2008). V-cyclin/CDK6 complex is constantly active since it does
not require phosphorylation of the CDK6 by CDK-activating kinase (CAK) (Child and Mann 2001,
Kaldis, Ojala et al. 2001). Furthermore, it can escape from CDK inhibitor control since it is resistant
against CKIs p27KIP1, p21CIP1 and p16INK4a (Swanton, Mann et al. 1997). V-cyclin/CDK6 can
proceed the cell cycle from G1 phase to S-phase and enable DNA replication by phosphorylating
Rb and components of DNA replication machinery (Godden-Kent, Talbot et al. 1997, Laman,
Coverley et al. 2001). V-cyclin overexpression is linked to increased genomic instability which
triggers p53 dependent DDR and ultimately leads to apoptosis or senescence (Verschuren,
Klefstrom et al. 2002, Koopal, Furuhjelm et al. 2007). Thus v-cyclin expressing cells are able to
survive only in the absence of p53 (Verschuren, Klefstrom et al. 2002, Verschuren, Hodgson et al.
2004). Interestingly it has been shown that v-cyclin/CDK6 can phosphorylate and inactivate
selectively cellular Bcl-2 but not KSHV encoded viral Bcl-2 (vBcl-2, ORF16) and promote
apoptosis in v-cyclin overexpressed cells (Ojala, Yamamoto et al. 2000).
In addition to the inhibition of intrinsic apoptosis, KSHV is able to inhibit extrinsic apoptosis and
promote  cell  survival.  KSHV encodes  a  homologue  of  cellular  FLIP (vFLIP)  which  contains  two
DED domains which bind FADD and prevent the activation of procaspase-8 by CD95 death
receptor (Thome, Schneider et al. 1997). Additionally vFLIP can bind procaspase-8 directly and
prevent its cleavage and activation (Belanger, Gravel et al. 2001). Furthermore, vFLIP is able to
promote survival of KSHV-infected cells by activating NF-κB signaling through binding to the IκB
complex (Liu, Eby et al. 2002).  The maintenance of continuously active NF-Kb signaling by vFLIP
is crucial for PEL cell survival (Keller, Schattner et al. 2000, Guasparri, Keller et al. 2004).
5.3.1. Manipulation of cell cycle during the lytic phase
Studies so far have led to the assumption that herpesviruses induce G1 arrest to ensure efficient lytic
replication (Flemington 2001). Similar findings have also been reported for KSHV lytic replication.
For instance, it was shown that TPA-induced reactivation of PEL cells causes an increase in the
fraction of cells in G1 phase. Similarly, overexpression studies showed that the lytic viral protein
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K8 (RAP) facilitated G1 arrest by activating the expression of p21Cip-1 and by inhibiting the
cyclinA/E/Cdk2 complex (Wu, Tang et al. 2002, Izumiya, Lin et al. 2003). A more recent study has
identified vIRF4 as another inducer of G1 arrest. The same study showed that repressing the
expression of cyclin D, a promoter of G1 progression, led to increased lytic replication (Lee, Mitra
et al. 2015).
Taken together, these studies suggest that K8 and vIRF4 could support lytic replication by
inhibiting host cell entry into S-phase. And, as speculated by Eric Flemington in his review, it
probably is the mechanism by which herpesviruses ensure a sufficient supply of nucleotides for
lytic replication (Flemington 2001).
5.3.2. Manipulation of apoptosis during the lytic phase
Premature cell death of the reactivated cells is a critical cellular process that the virus needs to
prevent  or  delay  in  order  to  ensure  efficient  viral  transcription,  replication  and  production  of
infectious progeny. This is evident for KSHV from the number of viral genes in its genome devoted
to the inhibition of this process. Early lytic proteins of KSHV inhibit apoptosis by interfering with
the function of p53. RTA has been shown to interfere with the transcriptional activity of p53 and
prevent apoptosis (Gwack, Hwang et al. 2001).  K8 (RAP) has been shown to bind and inhibit p53
and apoptosis (Park, Seo et al. 2000). Overexpression studies have suggested that K8 binds to and
sequesters p53 to PML bodies, thereby inhibiting apoptosis (Katano, Ogawa-Goto et al. 2001).
The lytic gene ORF16 encodes a homolog of the human Bcl-2 protein called viral Bcl-2 (vBcl2).
vBcl2 is anti-apoptotic protein  (Sarid, Sato et al. 1997) that binds to many pro-apoptotic BH-3
proteins like Noxa, Bik, PUMA, Bak, Bax, Bid, Bim and Bad (Huang, Petros et al. 2002, Loh,
Huang et al. 2005, Flanagan and Letai 2008). vBcl2 escapes from cellular regulation since it lacks
the cleavage site that the human Bcl-2 protein harbors and that makes the latter sensitive to cleavage
by caspase-3. In cells that are fully committed to apoptosis, this cleavage converts Bcl-2 from an
anti- to pro-apoptotic protein (Bellows, Chau et al. 2000). Moreover, when complexed with CDK6,
the latent viral protein v-cyclin can phosphorylate and selectively inactivate Bcl-2 but not vBcl-2
(Ojala, Yamamoto et al. 2000).  Knock out of ORF16 from the KSHV genome leads to a decrease
in both lytic replication and production of viral particles (Gelgor, Kalt et al. 2015, Liang, Chang et
al. 2015). However, at least in cell culture systems, the anti-apoptotic function of vBcl2 was not
required for lytic replication, as deletions or mutations that impaired only this function of the
protein had no effect on lytic replication. Since depletion of the full protein did impair reactivation,
vBcl2 must have an as of yet unidentified role in the KSHV lytic cycle (Liang, Chang et al. 2015).
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K7 (vIAP) is a lytic glycoprotein sharing structural similarity with the anti-apoptotic human protein
survivin. vIAP inhibits apoptosis by binding active caspase-3 and blocking its function. At the
molecular level, vIAP binds both activated caspase-3 and Bcl-2 to bridge these two proteins
together and thus inhibits caspase-3-mediated apoptosis (Wang, Sharp et al. 2002).
KSHV encodes four viral homologues of interferon regulatory factors (vIRF1-4) expressed in latent
(vIRF3) and lytic infection (vIRF1,2,4) that interfere with the host antiviral responses that would
otherwise lead to growth suppression and apoptosis (Moore and Chang 2003). Both vIRF1 and
vIRF3 bind to p53 and impair its function (Nakamura, Li et al. 2001, Rivas, Thlick et al. 2001, Seo,
Park et al. 2001, Baresova, Musilova et al. 2014). Furthermore, vIRF4 stabilizes MDM2 to degrade
p53 (Lee, Toth et al. 2009) and vIRF1 interacts with ATM to inhibit the phosphorylation of p53 at
Ser 15. When unphosphorylated p53 is rapidly degraded, the strong DDR that is induced during
KSHV infection is impaired, and this can lead to premature cell death (Shin, Nakamura et al. 2006).
A recent study that was designed to discover novel KSHV-encoded proteins that exhibit p53-
inhibitory function identified the late lytic structural genes ORF22, ORF25 and ORF64
(Chudasama, Konrad et al. 2015). These structural proteins inhibited p53-induced apoptosis and
p53 transactivation of the apoptotic genes Bax and PIG3 (Chudasama, Konrad et al. 2015).
In summary, during lytic infection, KSHV lytic proteins are able to constitutively activate cell
proliferation, manipulate the regulation of the cell cycle and inhibit apoptosis in order to both
prevent premature cell death and secure efficient lytic replication and production of viral progeny.
5.4. The lytic replication phase is necessary for the progression of KSHV associated
malignancies
Many clinical studies have shown that virus reactivation is a critical step in the appearance and
progression of KS. Serological studies have revealed that detection of viral DNA in blood is
associated with the appearance of new KS lesions. KSHV seropositive patients who carry KSHV-
infected peripheral blood mononuclear cells (PBMC) have a 10-fold higher incidence of developing
KS than patients whose PBMCs are not infected (Whitby, Howard et al. 1995, Moore, Kingsley et
al. 1996, Keller, Zago et al. 2001, Cannon, Dollard et al. 2003, Engels, Biggar et al. 2003). Elevated
viral loads in PBMCs correlate with the severity of KS progression (Campbell, Borok et al. 2000,
Boneschi, Brambilla et al. 2001, Broccolo, Tassan Din et al. 2016).
These correlations suggest that virus production is required for disease progression. Confirming this
notion,  treatment  of  KS  patients  with  the  drugs  Ganciclovir  or  Foscarnet,  both  inhibitors  of
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herpesvirus DNA synthesis, decrease the risk of KS development and slow down KS progression
(Jones, Hanson et al. 1995, Martin, Kuppermann et al. 1999, Robles, Lugo et al. 1999).
Interestingly although PEL cells are mostly latently infected, inhibitors of KSHV lytic replication:
Ganciclovir  and  Cidofovir  has  shown  to  be  potential  therapeutic  modalities  in  treatment  of  PEL
(Luppi, Trovato et al. 2005, Stingaciu, Ticchioni et al. 2010, Pereira, Carvalho et al. 2014)
underlining the importance of the lytic cycle on progression of the KSHV associated cancers.
Lytic cycle is not only required for viral shedding and maintenance of persistent infection; it is also
directly and indirectly advancing KS pathogenesis by promoting inflammation, angiogenesis and
cell growth via lytic gene products (Ganem 2010, Andrei and Snoeck 2015). Therefore, inhibition
of the lytic cycle or targeting of cellular processes utilized and activated by KSHV is an attractive
target for therapeutic strategies.
5.5. Latest discoveries on therapeutic modalities of KSHV associated cancers
Most of the current pre-clinical studies in KSHV associated cancers have been performed with
inhibitors targeting cellular pathways, which are active in KSHV infected cells (Antar, El Hajj et al.
2014, Andrei and Snoeck 2015).
PEL cell survival is dependent on vFLIP activated NF-κB signaling therefore several small
molecule inhibitors targeting this survival pathway has shown to be potential in pre-clinical studies.
As in the study where NF-κB was inhibited with BAY 11-7082 exerts a strong reduction of PEL
cell survival (Keller, Schattner et al. 2000). And moreover proteasome inhibitors MG-132,
lactacystin, proteasome inhibitor I and Bortezomib suppress NF-κB activity of PEL cells and
promote apoptosis (Matta and Chaudhary 2005, Saji, Higashi et al. 2011). And in the recent study
was discovered that by inhibition of NEDDylation with small molecule inhibitor (MLN4924) NF-
κB signaling was suppressed causing cell death and inhibition lytic replication of PEL cells
(Hughes, Wood et al. 2015). Interestingly diallyl trisulfide (DAT), a main component of garlic oil,
was shown to inhibit NF-κB and suppress PEL formation in xenograft mice (Shigemi, Furukawa et
al. 2016).
Immunomodulatory drugs (IMiDs) like thalidomide or second generation IMiDs lenalidomide and
pomalidomide have been shown to have anti-tumor activity on multiple myeloma and other B-cell
lymphomas (Shortt, Hsu et al. 2013) and recently it has been discovered that anti-tumor activity of
IMiDs are based on their ability to induce degradation of B-cell specific transcription factors Ikaros
family zinc finger 1 and 3  (IKZF1 and IKZF3) (Kronke, Udeshi et al. 2014). A recent study where
these IMiDs were tested on PEL showed that lenalidomide and pomalidomide induced G1 arrest by
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downregulating IRF4 and its downstream target c-Myc. This study showed that IMiDs were
targeting IKZF1 which led to downregulation of IRF4 and thus downregulation of c-Myc. And by
targeting c-Myc expression with inhibitor (JQ1) targeting Bromodomain containing 4 (BRD4),
antiproliferative effect of IMiDs were enhanced and co-treatment with JQ1 and lenalidomide
increased survival of PEL xenograft mice (Gopalakrishnan, Matta et al. 2016). As it has been shown
that  c-Myc  and  IRF4  plays  a  role  in  the  maintenance  of  latent  infection  (Li,  Chen  et  al.  2010,
Forero, McCormick et al. 2014), one would think that IMiDs would induce lytic replication
however it was not detected in this study (Gopalakrishnan, Matta et al. 2016). Importantly there has
been published a case report describing the successful treatment of a PEL patient with lenalidomide
(Antar, El Hajj et al. 2014). And furthermore lenalidomide has shown to be potential drug against
KS as case reports described successful treatment of 3 patients with HIV-related KS and partial
response of advanced HIV-related visceral KS patient (Martinez, Tateo et al. 2011, Steff, Joly et al.
2013).
Hepatocyte growth factor (HGF) is the ligand for the receptor tyrosine kinase c-MET and activation
of this pathway modulate several downstream signaling pathways regulating cellular processes such
as proliferation, survival, migration or angiogenesis. Thus HGF/c-MET pathway is promising drug
candidate in anticancer therapies (Gherardi, Birchmeier et al. 2012). PEL cells have active HGF/c-
MET pathway (Capello, Gaidano et al. 2000) and KSHV infection is activating this pathway (Dai,
Trillo-Tinoco et al. 2015). And when PEL cells were treated with c-MET inhibitor (PF-2341066) it
induced G2/M cell cycle arrest and DNA damage mediated apoptosis of PEL cells and suppress
tumor growth of PEL xenograft mice (Dai, Trillo-Tinoco et al. 2015).
mTOR is serine/threonine kinase regulating protein synthesis in response to nutrient availability and
enviromental stress  (Ma and Blenis 2009).  mTOR facilitate protein synthesis by phosphorylating
ribosomal protein S6 kinase (S6KB1), which phosphorylate ribosomal S6 protein, which is a
component  of  40S ribosome (Ma and  Blenis  2009).  PI3K/AKT/mTOR pathway is  critical  for  the
survival of KSHV-infected cells (Sin, Roy et al. 2007, Bhatt, Bhende et al. 2010). Importantly
inhibition of mTOR with Rapamycin treatment led to complete regression of classic-KS and
iatrogenic KS tumors (Stallone, Schena et al. 2005, Diaz-Ley, Grillo et al. 2015). Rapamycin and its
analogs were tested in KS xenograft mouse model, which was obtained by injecting subcutaneously
KSHV infected endothelial cells. Rapamycin inhibited angiogenesis of xenograft tumor cells and
reduced tumor growth and in KSHV infected endothelial cells secretion of VEGF-1 was inhibited
(Roy, Sin et al. 2013). Rapamycin was found to have response in inhibition of cell growth of PEL
cells and PEL tumor in xenograft mouse (Sin, Roy et al. 2007). Interestingly KSHV late lytic gene
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ORF36 encoding serine/threonine viral protein kinase (vPK) has been very recently found to
resemble human S6KB1. vPK was found to phosphorylate S6 and promote protein synthesis of
endothelial and epithelial cells. vPK was able to sustain S6 phosphorylation even in the presence of
Rapamycin, indicating that vPK is able to phosphorylate S6 without mTORC. Furthermore vPK
enhance cellular proliferation and was shown to be vital for production of viral particles. vPK was
shown to induce anchorage independent growth of fibroblasts and tubule formation of HUVEC
cells (Bhatt, Wong et al. 2016). Thus lytic cycle could cause resistance to Rapamycin treatment or
prolonged treatment could develop drug resistance. Indeed it has been seen in PEL xenograft mice
that initial response of Rapamycin treatment was turned into rapid drug resistance (Gasperini and
Tosato 2009).
Another example on drug resistance of lytic KSHV infected cells was seen with Nutlin-3 treatment
which induces p53-mediated cell cycle arrest and apoptosis of latently infected PEL cells, but cells
undergoing lytic infection were showing drug resistance against Nutlin-3 (Sarek, Kurki et al. 2007,
Sarek, Ma et al. 2013). Furthermore by targeting cysteine-glutamate transporter (xCT) with small-
molecule inhibitor caspase dependent apoptosis could be induced in PEL cells and suppress tumor
growth of PEL xenograft mice. However this treatment induced production of ROS and induced
reactivation of KSHV (Dai, Cao et al. 2014).
As indicated by these examples on current therapeutic modalities to treat KSHV induced cancers it
is important not only target latently infected cells, but also inhibit lytic cycle. And as shown in a
study where latent PEL cells were induced for lytic reactivation with HDAC inhibitor (SAHA) and
co-treated with proteasome inhibitor (Bortezomib) which inhibited late lytic replication and release
of viral progeny offers promising therapeutic modality to induce apoptosis of KSHV infected cells
without increased viremia (Bhatt, Ashlock et al. 2013).
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AIMS OF THE STUDY
1. To identify the cellular targets of the KSHV encoded miRNAs (I)
2. To test if small molecule inhibitors of anti-apoptotic Bcl-2 family proteins induce cell death of
KSHV infected cells and provide new anti-viral drugs (II)
3. To identify new host epigenetic regulators which are regulating KSHV lytic reactivation (III)
4. To discover protein-protein network of v-cyclin and host cell proteins
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MATERIALS AND METHODS
The materials and methods of this study are listed below, with detailed description in the original
publications, here referred to by Roman numerals.
Table 2. Cell lines used in this study
Cell line Description Source or reference Used in
BC-3 Patient derived KSHV
positive human
primary effusion
lymohoma cell line
(PEL)
National Institutes of
Health AIDS Research
and Reference Reagent
Program (catalog #
3233 from McGrath
and Ganem)
I, II, III
CZE EBV transformed
Human
lymphoblastoid cell
line
Sarek, Kurki et al.
(2007)
unpublished v-cyclin
study
DG-75 Human Burkitt
lymphoma cell line
ATCC I
EA.hy926 Human endothelial
cell line, cell hybrid of
human umbilical vein
endothelial cells and
human lung carcinoma
cell line A594
Prof. Kari Alitalo
(Edgell, McDonald et
al. 1983)
I
HEK 293 Flp-In Human embryonic
kidney cell line.
Contain a single stably
integrated FRT site at
a transcriptionally
active genomic locus.
Invitrogen unpublished v-cyclin
study
iSLK.219 Tetracycline inducible
SLK cells harboring
recombinant KSHV
(rKSHV.219, (Vieira
and O'Hearn 2004))
Dr. J. Myoung and
Prof. D. Ganem
(Myoung and Ganem
2011)
II, III
K-iLEC De novo KSHV-
infected E6/E7
immortalized human
lymphatic endothelial
cell line
Promocell,
E6/E7 immortalization
previously described in
(Moses, Fish et al.
1999)
I
QBI-HEK 293A Adenovirus 5
immortalized primary
human embryonic
kidney cell line
QBiogene I
rKSHV-SLK rKSHV.219-de novo
infected SLK cell line
This study III
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SLK Originally established
from a mucosal KS
lesion, but later
identified as human
clear-cell renal-cell
carcinoma cell line.
National Institutes of
Health AIDS Research
and Reference Reagent
Program
II, III
rKSHV-Vero rKSHV.219 de novo
infected monkey
kidney cells
J.Vieira (Vieira and
O'Hearn 2004)
II, III
Table 3. Primary antibodies used in this study
Antibody Description Source of reference Used in
Bap1(C-4) Mouse monoclonal
IgG antibody against
human BAP1
Santa-Cruz
Biotechnology
unpublished v-cyclin
study
Caspase-3 Mouse monoclonal
antibody against
human caspase-3
Millipore
MAB4603
I
Cdc2 p34 (PSTAIRE) Rabbit polyclonal IgG
antibody against
PSTAIRE domain of
human CDK1
Santa-Cruz
Biotechnology
unpublished v-cyclin
study
Cdk7(C-4) Mouse monoclonal
IgG antibody against
human CDK7
Santa-Cruz
Biotechnology
unpublished v-cyclin
study
Cleaved caspase-3 Rabbit monoclonal
antibody against
human cleaved
caspase-3
Cell signaling
Asp175
I
Histone H4(F-9) Mouse monoclonal
IgG antibody against
human Histone H4
Santa-Cruz
Biotechnology
unpublished v-cyclin
study
K8.1 A/B Mouse monoclonal
antibody against K8.1
ABI Biotechnologies III
KSHV ORF57 (MTA) Mouse monoclonal
antibody against
ORF57
Santa Cruz
Biotechnology
sc-135746,
III
KSHV ORF59 Mouse monoclonal
antibody against
ORF59
(Chan, Bloomer et al.
1998)
III
LANA (HHV8-
ORF73)
Rat monoclonal
antibody against
LANA
ABI Biotechnologies III
MDM2 (2A10) Mouse monoclonal
antibody against
MDM2
Abcam III
MDM2 (IF-2) Mouse monoclonal
antibody against
MDM2
Calbiochem III
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MDM2 (SMP14) Mouse monoclonal
antibody against
MDM2
Abcam III
Mono-HA.11(16B12) Mouse monoclonal
IgG antibody against
influenza
hemagglutinin epitope
Covance unpublished v-cyclin
study
MYBBP1A Rabbit polyclonal IgG
antibody against
human MYB pinding
protein 1a
Novus Biologicals unpublished v-cyclin
study
p21Cip-1 Rabbit polyclonal
antibody against
human p21Cip-1
Santa Cruz
Biotechnology
C-19, sc-397
III
p53 Mouse monoclonal
antibody against
human p53
GeneSpin
DO-1
III
p53 Rabbit polyclonal
antibody against
human p53
Santa Cruz
Biotechnology
FL-393
III
Peg10(C-7) Mouse monoclonal
IgG antibody against
human Peg10
Santa-Cruz
Biotechnology
unpublished v-cyclin
study
pH3S10 Rabbit polyclonal
antibody against
phosphorylated histone
3 serine 10
Upstate Biotechnology III
USP9Y Mouse monoclonal
IgG antibody against
human USP9Y
Sigma Aldrich unpublished v-cyclin
study
v-cyclin Rabbit polyclonal IgG
antibody against v-
cyclin
Self-made unpublished v-cyclin
study
γ-tubulin Mouse monoclonal
antibody against
human γ-tubulin
Sigma-Aldrich
GTU-88
I, III, unpublished v-
cyclin study
rKSHV.219 production and infection of SLK cells (studies II and III)
The rKSHV.219 virus contains, in addition to all the KSHV genes, a gene coding for green
fluorescent protein (GFP), the expression of which is under the control of a cellular constitutively
active promoter (EF-1α), and a gene coding for red fluorescent protein (RFP), the expression of
which  is  under control of the viral  lytic PAN promoter (Vieira and O'Hearn 2004).  rKSHV-Vero
cells were used to produce infectious rKSHV.219 virus as described in (Vieira and O'Hearn 2004).
Briefly,  70%  to  90%  confluent  rKSHV-Vero  cells  in  100  or  150  mm  dish  were  reactivated  by
adding 3- 7 ml of a recombinant baculovirus (BacK50) expressing the KSHV lytic activator ORF50
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(RTA) for 2 hours at room temperature (RT) and 6-8 hours at 37°C at 5% CO2, which after BacK50
was removed, and replaced with complete media (DMEM:RPMI; in 40:60 ratio) containing 1,35
mM sodium butyrate (NaB, Sigma-Aldrich). Supernatants containing rKSHV.219 were collected 48
hours later and cell debris was spin down by centrifugation at 1200 rpm for 5 minutes and
supernatant was filtered through 0.45 μm syringe filter (Millipore) to remove the cell debris. Virus
supernatant was concentrated by ultracentrifugation at 18 000 rpm (SW-32-Ti rotor, Beckman
Coulter)  for  2  hours  at  4°C.  Virus  pellet  was  resuspended  with  100  μl  PBS overnight  at  4°C and
concentrated virus supernatant was snap froze and stored in liquid N2.
SLK cells were plated at a density 2x105 cells per well in a six-well dish and were infected the next
day with concentrated rKSHV.219 virus supernatant in the presence of 8 μg/ml polybrene to
enhance their infectivity. The plates were spin-transduced by centrifugation at 1,050 g (Heraeus
Multifuge) for 30 minutes RT. Cells were returned to 37°C at 5% CO2 for 2 hours, after which the
rKSHV.219 supernatant was replaced with complete DMEM media. Cells were routinely cultured
in the presence of 3,5 μg/ml puromycin. Infected cells were grown in the presence of the puromycin
for about two weeks to obtain a 100% infected stable cell line.
Cell culture and virus reactivation (studies I, II, III and unpublished v-cyclin study)
EA.hy926, SLK, rKSHV-SLK and iSLK.219 cells were cultured in a humidified 5% CO2
atmosphere at 37°C in DMEM medium supplemented with 10% FCS, 100 U/ml penicillin G, and
100 μg/ml streptomycin. BC-3 and CZE cells were grown in RPMI 1640 medium supplemented
with 10% FCS, 100 U/ml penicillin G and 100 μg/ml streptomycin and 50 μM ß-Mercaptoethanol.
HUVEC cells were grown in endothelial basal medium (Promocell) supplemented with 10% FCS,
gentamicin, amphotericin and supplement kit provided with the media.
To obtain KSHV miRNA expressing cells, primary and E6/E7 immortalized HUVEC cells were
transduced with lentiviruses (pLENTI6/V5; Invitrogen) encoding EGFP or 10/12 KSHV miRNA
cluster (K10/12) and maintained under blasticidin selection (5 μg/mL) in endothelial basal medium.
To obtain immortal lymphatic endothelial cells (iLECs) and E6/E7 immortalized HUVEC cells
primary human LEC and HUVEC cells (Promocell) were immortalized by the HPV oncogenes
E6/E7 as previously described (Moses et al., 1999). iLEC cells were maintained in endothelial basal
medium (Promocell) supplemented with 5% human AB serum (HS; Sigma, St. Louis, Mo.). To
obtain K-iLEC cells, iLEC cells were infected with wild type KSHV virus as described in
publication I.
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iSLK.219 cells were grown in the presence of G418 (250 mg/ml), Hygromycin (400 μg/ml) and
puromycin (10 μg/ml) and maintained as described (Myoung and Ganem 2011).
To induce KSHV lytic replication, rKSHV-SLK cells were treated as described (Cheng, Weidner-
Glunde et al. 2009), iSLK.219 cells were treated 0.2 μg/ml doxycycline and 1.35 mM sodium
butyrate (NaB; Sigma, St Louis, MO), and BC-3 cells were treated with 1.35 mM NaB or 20 ng/ml
12-O-tetradecanoylphorbol-13-acetate (TPA; Sigma).
HEK 293 Flp-In cell lines were cultured with high-glucose (4,5g/l) Dulbecco’s modified Eagle’s
medium (HG-DMEM). All Flp-In cell lines used in this study were grown in media containing
100μg/ml Hygromycin B (Invitrogen). Induction of v-cyclin expression in Flp-In 293 cell lines was
performed by addition of fresh culture medium (HG-DMEM, 50U/ml penicillin G, 50U/ml
streptomycin and 2mM L-glutamine) containing 1000ng/ml tetracycline (Sigma, 5mg/ml stock in
absolute ethanol) onto the cells. For immunoblotting and affinity purification cells were 70%
confluent at the time of induction.
miRNA inhibition with 2′O-methylated oligonucleotides and Tiny LNA treatment (study I)
BC-3 cells were seeded in 6-well plates and transfected with 60 nM 2′O-methylated
oligonucleotides (provided by G. Meister) which are acting as RNA analogs binding and inhibiting
miRNA function. Oligonucleotides were transfected with Oligofectamine (Invitrogen) and
transfections were performed according to manufacturer's instructions. Total proteins were
extracted for analysis 48 h after transfection.
BC-3 cells were seeded in 6-well plates and incubated with 1.5 μM short Locked Nucleic Acid
oligonucleotides (tiny LNAs), which antagonize the function of miRK12-1/3/4 or the control C.
elegans miR-67 by targeting miRNA seed sequence. Cells were incubated with Tiny LNAs for 48 h,
or 6 days.
K-iLEC cells were seeded replacing the medium twice (day 2 and 5), prior to harvesting the
cells.one day before at 5×104 cells/well on 24-well plates and treated with two doses of Tiny LNA
oligonucleotides (48 h+48 h) at a final concentration of 1,5 μM.
Measurement of apoptosis by TUNEL assay (study I)
Tiny LNA treated K-iLEC cells were induced for apoptosis with 500 μM Etoposide (Sigma
Aldrich) or DMSO (mock). Cells were fixed with 4% Paraformaldehyde (EMS, Hatfield, PA) 24 h
after the apoptosis induction. Apoptotic cells were detected with TdT-mediated dUTP nick end
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labeling (TUNEL) assay according to manufacturer's instructions (In situ Cell Death Detection Kit,
TMR red, Roche, Mannheim, Germany). Microscopic analysis of apoptotic cells was performed
with a Zeiss Axioplan 2 fluorescent microscope (Carl Zeiss, Oberkochen, Germany). Images were
acquired with a Zeiss Axiocam HRc, using Zeiss AxioVision (version 4.5 SP1) and Adobe
Photoshop software (version 7.0; Adobe, San Jose, CA).
Measurement of cell viability with Cell titer glo assay (study II)
Efficacy and cytotoxicity testing were performed in 96-well plate format. 10 000 cells were seeded
per well and cells were grown for 24 h. ABT-263 or Obatoclax (Munich, Germany) were added to
the  cells  in  3-fold  dilutions  at  7  different  concentrations  starting  from  10  μM  concentration.  No
compounds  were  added  to  the  control  wells.  Cell  viability  was  measured  using  a  Cell  Titre  Glo
assay (CTG; Promega, Southampton, UK). Luminescence was read with PHERAstar FS plate
reader (BMG Labtech, Ortenberg, Germany).
Quantitative real-time PCR (study II, III and unpublished v-cyclin study)
Total RNA was prepared by using the RNAeasy kit according to instructions from the manufacturer
(Qiagen, Valencia, CA). RT-PCR was performed with TaqMan Reverse Transcription Reagents kit
(Roche Diagnostics, Indianapolis, IN) according to the manufacturer's protocol. Real-time PCR
conditions and sets of primers for ORF16 (vBcl-2) sense: 5´-GTGTTGGCCATTGAAGGGAT-3´;
antisense: 5´-GTAAAACGGCCAAAGCAAAG-3´, ORF72 (v-cyclin) sense: 5´-
AGCTGCGCCACGAAGCAGTCA-3´; antisense: 5´-CAGGTTCTCCCATCGACGA-3´, ORF74
(vGPCR) sense: 5’-CGCTGCACTGTTAATTGCAT-3’; antisense: 5’-
GTCGCCTTAGCAGAGTGTCC-3’, ORF50, ORF57, K8.1 and human beta-actin were essentially
as described previously (Dittmer, Stoddart et al. 1999, Fakhari and Dittmer 2002). For statistical
evaluation of qRT-PCR data was performed as in (Cheng, Pekkonen et al. 2012).
Cell spot microarray siRNA screen (study I)
The custom-made siRNA library (Qiagen) was complexed with lipid transfection agents and
Matrigel (BD Biosciences) and spotted/arrayed onto an untreated hydrophobic polystyrene surface.
rKSHV-SLK  cells  were  seeded  onto  the  array  as  a  30  000  cells  /ml  suspension,  and  allowed  to
adhere for 15 min. Unattached cells were then washed off.  After 48 hours, rKSHV.219 was
induced for reactivation by treating cells with recombinant baculovirus (BacK50) expressing ORF
50 (RTA; a gift from J. Vieira; University of Washington) for 2 h at room temperature and 6 hours
in +37°C. As a positive control for maximal reactivation, one array was in addition to BacK50
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treatment also treated with 1.35 mM sodium butyrate (Sigma). Following induction of rKSHV
reactivation, cells were incubated for an additional 30 hours, fixed with 4% paraformaldehyde
(PFA; Electron Microscopy Sciences) and processed for the analysis of GFP (marker of latent
infection) or RFP (marker of lytic reactivation) expression using a LS400 laser scanner (Tecan) to
obtain a single low resolution image of the whole array. From this image, the fluorescence of each
spot was quantified with the ArrayPro Analyzer v. 4.5 (Media Cybernetics Inc) to obtain the mean
intensity fluorescence value of the whole screen. Total raw mean intensities of signals for all cells
per spot were normalized using pin normalization to obtain the net intensities. The net intensity
value of each spot was then compared to that of the mean of the screen, used as a control, and thus
calculated standard score (Z-score) was calculated for each siRNA treatment. From this analysis,
siRNAs with Z-scores >2 s.d. were considered significant and cells re-imaged separately using an
Olympus Scan-R high content microscope (Olympus Europe, Munich, Germany) for phenotype
validation.
For validation of the screen results, iSLK.219 cells were plated on a 96-well dish (Perkin Elmer) at
the  density  of  3000  cells/well  24  hours  before  siRNA  transfection.  Cells  were  transfected  with
control or pooled siRNA oligos for MDM2 (4 siRNA oligos per gene, Qiagen) by DharmaFECT1
reagent (Dharmacon) according to the manufacturer’s instructions. 24 hours after transfection, the
cells were treated with a suboptimal dose 0.05 μg/ml of doxycycline to prime the lytic induction
and incubated for 52 hours. Cells were fixed with 4% PFA and the induction of RFP expression was
monitored by using an automated high-content fluorescence microscope (CellInsight, Thermo
Scientific).
Lentiviral production and transduction (study III)
Production of lentiviral supernatants was performed as described earlier (Koopal, Furuhjelm et al.
2007) with the addition of a concentration step where lentiviral supernatants were concentrated by
ultracentrifugation at +4°C and with 22.000 rpm speed (SW-32-Ti rotor (Beckaman Coulter).
To  silence  expression  of MDM2 or TP53, BC-3 cells were seeded at density 5x105 /ml and
transduced in the presence of 8 mg/ml polybrene (Sigma) in a 50 ml culture flask using 2 ml of
concentrated frozen lentiviruses expressing two different small hairpin (shRNA) sequences specific
for MDM2 (sh5-MDM2, sh3-MDM2) or p53 (sh1-p531, sh2-p53) and the corresponding scrambled
controls (sh-Scr) essentially as described in (Sarek, Jarviluoma et al. 2010). To establish cell lines
stably expressing sh-p53, the medium was changed at 48 hrs after transduction into a fresh medium
containing 3.5 μg/ml puromycin (Sigma) and maintained thereafter.
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Generation of the isogenic v-cyclin expressing cell line
To generate the v-cyclin expressing cell lines gateway cloning technology (Invitrogen) was utilized
to clone an expression plasmid (pcDNA5/FRT/TO/v-cyclin/SH/GW) containing the ORF72 (v-
cyclin) gene with a FRT recombination site, a hygromycin resistance gene and an N-terminal Strep-
tag and a Hemagglutinin epitope (SH)-tag. The expression of this construct is under the control of
tetracycline (tet)-operated (TO) CMV promoter. Two independent clones of v-cyclin expression
plasmids were cloned and named v-cyclin 1 (vcyc1) and v-cyclin 2 (vcyc2) and a control plasmid
expressing only HA- and Strep-tags (Ctrl). pcDNA5/FRT/TO/v-cyclin (1 and 2)/SH/GW expression
plasmids and pOG44 plasmid expressing Flippase (Flp) recombinase enzyme were co-transfected
into HEK293 Flp-In cells (Invitrogen). Co-transfection induced Flp mediated homologous
recombination between FRT sites of the cellular genome and expression plasmid. Hygromycin
resistance gene enables antibiotic selection of the isogenic v-cyclin cell clones.
Affinity purification and silver staining (unpublished v-cyclin study)
To determine binding partners of v-cyclin, affinity purification was performed by utilizing the
Strep-tag®  (IBA)  in  the  N-terminus  of  the  v-cyclin  protein.  The  expression  of  the  protein  was
induced for 24h by tetracycline (1000ng/ml) of the following 293 HEK Flp-In cell lines: v-cyclin1,
v-cyclin2 and empty, cultured in six 135 cm2 culture flasks. Thereafter the cells were washed once
with 1x PBS, detached with Trypsin- ethylenediaminetetraacetic acid (EDTA), pooled together and
harvested by centrifugation with 153 x g for 5 minutes.  Cell pellets used in this study were all
snap-frozen with liquid NO2 and thawed on ice in the presence on lysis buffer HNN (50mM
HEPES, pH 8; 150mM NaCl; 50mM NaF; 1mM PMSF; 1,5mM Na-vanadate; 0,5% NP-40; 1x
protease inhibitor cocktail (cOmplete, Roche)) on the day of purification. Thawed pellets were
homogenized into lysis buffer with Dounce homogenizator, subjected to rotary-incubation for 10
minutes and centrifuged 17 000 x g for 30 minutes at 4°C to separate soluble proteins from cell
debris. Individual supernatants were filtered through Poly Prep chromatography columns (Bio-Rad)
to further purify remaining lipids and debris from samples and applied further onto Strep-Tactin
columns  (IBA)  equilibrated  with  wash  buffer  (100mM  Tris-HCl  pH  8.0,  150mM  NaCl,  1mM
EDTA) and HNN lysis buffer respectively. Unbound proteins were washed from the column first
twice  with  HNN  lysis  buffer  followed  by  5  times  with  plain  HN  buffer  (50mM  HEPES,  pH  8;
150mM NaCl) without protease inhibitors or NP-40. Elution was performed with HN-buffer
containing 1mM biotin to outcompete bound strep-tag. Eluates were divided into two aliquots and
subjected to analysis by mass spectrometry or immunoblotting to identify proteins pulled-down
with the v-cyclin.
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To monitor purification of v-cyclin bait protein along the process, small aliquots were taken after
clarification of the lysate, from the first flow-through, and from final eluate. These samples were
then applied into two 15% polyacrylamide gels and subjected to silver staining and western blot
against anti-HA antibody to verify enrichment of the bait and its main binding partner respectively.
Silver staining was performed according to PageSilver Silver Staining Kit (Fermentas) instructions.
SDS-PAGE and Western Blotting (unpublished v-cyclin study)
Each 293 Flp-In cell line was washed once with 1x phosphate buffered saline (PBS), detached with
Trypsin- EDTA (1:250 Trypsin BD Difco) and harvested by centrifugation at 153 x g for 5 minutes.
Cell pellets were lysed into ELB lysis buffer 150mM NaCl; 50mM N-2-hydroxyethylpiperazine-N-
2-ethanesulfonic acid (HEPES), pH 7.4; 5mM EDTA; 0.1% Igepal; 1mM dithiothreitol DTT and 1x
cOmplete protease inhibitor cocktail (Roche, dissolved into the ELB) vortexed shortly and passed
through a 0,6mm needle (Microlance 3) to enhance lysis. Lysates were clarified by centrifugation at
17 000 x g for 20 minutes at 4°C. Protein concentration was measured from the supernatant with
Bio-Rad protein assay reagent. Protein standards were constituted from 10mg/ml bovine serum
albumin (BSA) stock (New England Biolabs). For sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) 5x Laemmli sample buffer (1M Tris-Cl,  pH 6.8; 5mM EDTA; 7,5%
SDS; 50% glycerol; 5% β-mercaptoethanol; 0.02% bromophenol blue)  was applied to each sample
to  a  final  concentration  of  1x  followed by  boiling  of  the  samples  for  5  minutes  at  95°C.  Proteins
from the samples were separated together with PageRuler Plus prestained protein ladder (Thermo
Scientific) on 8-,12- or 15% sodium dodecyl sulphate-polyacrylamide gels. After the SDS-PAGE,
proteins were transferred to nitrocellulose membrane (Protran, Whatmann) at room temperature for
45- to 1 h 45 minutes with semi-dry transfer using Owl electroblotting system (Thermo Scientific)
in semi-dry blotting buffer (47,8mM Tris; 38,6mM Glycine; 0,037% SDS; 20% methanol). The
non-specific binding sites in the membrane were blocked with 5%(w/v) skim milk (in 1x Tris-
buffered saline (TBS), 0,05% Tween20; 0,02% Sodium azide) (TBST) for 30 minutes at room
temperature followed by overnight incubation with the primary antibody at +4°C.
Analysis of v-cyclin interacting proteins with LC-MS/MS (unpublished v-cyclin study)
In order to identify v-cyclin interacting proteins from the affinity purified samples, the proteins
were reduced with 5 mM tris (2-carboxyethyl)phosphine (TCEP), alkylated with 10mM
iodacetamide,  and digested overnight to  peptides with 1μg trypsin (Promega). After the digestion
peptides were subjected to reverse-phase liquid chromatography and the eluting peptides analyzed
using Orbitrap Elite ETD (Thermo Scientific) mass spectrometer (Institute of Biotechnology
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Proteomics Unit) by our collaborator Docent Markku Varjosalo. The resulting LC-MS/MS spectra
from the analysis were searched using SEQUEST spectrometry data analysis program after which
the data was subjected to a stringent contaminant filter, a database compiled from three hundred
individual affinity purification pull down experiments. All the proteins that appeared in over 10% of
the database’s pull down experiments and had a match in the obtained SEQUEST data, were
considered contaminants and discarded when compiling the final list of v-cyclin interacting
proteins. In addition, the numerical values of common interacting peptides from HEK293 empty
sample were subtracted from the vcyc1- and vcyc2 samples to obtain number of interactions
resulting from the presence of v-cyclin solely.
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RESULTS AND DISCUSSION
1. KSHV-encoded miRNAs target effector caspase 3 to inhibit apoptosis in latently infected
cells (I)
1.1 KSHV-encoded miRNAs target caspase 3
KSHV-encoded miRNAs deregulate host cell proliferation, apoptosis and cell survival and have an
important role in the development of KSHV-associated cancers (Zhu, Haecker et al. 2013). It is thus
important to investigate the function of these virally encoded miRNAs and identify their cellular
targets. To this end, we established two cell lines, DG-75 (derived from B-cells) and EA.hy926
(derived from endothelial cells), stably expressing the intronic cluster of KSHV-encoded miRNAs
(miR-K12-1 to miRK12-9 and miR-K12-11 named K10/12), and performed microarray analysis of
cell lines stably expressing the cluster of KSHV encoded miRNAs. As a control we used EGFP
expressing DG-75 and EA.hy926 cells. B-cells and endothelial cells were chosen because they
represent the model system for KSHV-associated diseases (Ganem 2010). Global gene expression
was analyzed from these cell lines by Affymetrix Human Genome U133 Plus 2.0 microarrays.
Transcripts with at least one matching seed sequence to one of the KSHV miRNA and whose
expression was at  least  1.4 fold lower than in the EGFP control cells were considered as putative
KSHV  miRNA  target.  The  results  of  this  analysis  revealed  hundreds  of  putative  KSHV  miRNA
targets (Putative KSHV miRNA targets in DG-75 cells are listed in dataset S2 and in EA.hy926
cells are listed in dataset S3 in I).
The findings from the microarray study were validated with a reporter gene assay in 293A cells co-
transfected with plasmids encoding the KSHV miRNA cluster (pCDNA-K10/12) and the firefly
luciferase gene fused with the 3’UTR of the putative miRNA target mRNA (psi-CHECK-2). We
decided to validate 16 putative targets related to cell cycle, apoptosis and DNA damage. As a
positive control in this assay we used the previously validated KSHV miRNA target osteopontin
SPP1 (Samols,  Skalsky  et  al.  2007).  When  compared  to  the  control  EGFP-expressing  cells,  a
significant downregulation of the luciferase signal (30-50%) was observed when the K10/12 cluster
was  co-expressed  with  the  3’  UTR  of  the SPP1 positive control and the newly identified targets
RAD51AP1 (RAD51-associated protein) and CASP3 (Fig. 4B in I).
The CASP3 gene codes for the apoptosis effector caspase 3 (Hengartner 2000). To confirm that the
KSHV miRNAs target the expression of endogenous caspase 3, we established primary and E6/E7
immortalized endothelial cell lines (HUVEC) stably expressing the K10/12 miRNA cluster or
EGFP as a control. The endogenous protein levels of caspase 3 were analyzed by immunoblotting.
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When compared to the EGFP expressing control HUVEC, a clear reduction of the endogenous
caspase 3 protein levels was observed in the K10/12 expressing HUVEC (Fig. 7D in I), thus
confirming the results of the transcriptomic analysis.
Another putative KSHV miRNA target validated from microarray study was RAD51AP1, which is
involved in the repair of DSBs in homologous recombination (HR) (Dunlop, Dray et al. 2012).
KSHV infection has been reported to induce chromosomal instability of primary endothelial cells
and genomic instability is also observed in PEL cells (Pan, Zhou et al. 2004, Nair, Pan et al. 2006).
Moreover, KSHV infection induces DDR (Verschuren, Hodgson et al. 2004, Koopal, Furuhjelm et
al. 2007) and the activation of ATM is required for the maintenance of latency (Jha, Upadhyay et al.
2013, Singh, Dutta et al. 2014). How the downregulation RAD51AP1 contributes to viral infection,
genome instability and DDR remains to be established.
Our transcriptomic analysis showed that the mRNA level of CASP3 and endogenous protein levels
of caspase-3 were significantly decreased upon expression of the KSHV miRNA cluster.
Interestingly similar results have been obtained with EBV encoded miRNAs as they have been
found to target CASP3 directly and indirectly by suppressing BAD and to inhibit apoptosis to
maintain latent infection (Vereide, Seto et al. 2014, Lin, Tsai et al. 2015, Kim, Choi et al. 2016).
Next we validated is KSHV K10/12 miRNA cluster inducing downregulation of CASP3 in KSHV
infected cells.
1.2 Depletion of KSHV miRNAs upregulates caspase 3 expression in KSHV-infected PEL cells
As we were able to demonstrate that cells expressing KSHV miRNAs have reduced levels of
endogenous caspase 3, we studied whether the downregulation of caspase 3 also occurs in KSHV-
infected  cells  and  if  this  effect  is  due  to  the  expression  of  the  KSHV miRNAs.  To  address  these
questions, we used BC-3 cells, a KSHV-naturally-infected cell line derived from a patient affected
by primary effusion lymphoma (PEL). The expression of KSHV miRNAs identified to target
CASP3 (Fig 5B in I, miR-K12-1, K12-3, K12-4-3p) were silenced with 2’-O-methylated (2’OMe)
antisense oligoribonucleotides (Meister, Landthaler et al. 2004) or short Locked Nucleic Acid
oligonucleotides (tiny LNAs; (Obad, dos Santos et al. 2011)). As a control, cells were treated with
antisense oligonucleotides against a non-relevant miRNA (miR-67). Compared to the control
treated cells, we could detect a modest but significant upregulation of caspase 3 mRNA and protein
levels in BC-3 cells treated with antisense oligos against the viral miRNAs (Fig. 7E-G in I).
This result indicates that KSHV-encoded miR-K12-1, miR-K12-3 and miR-K12-4-3p target the
caspase 3 expression in PEL cells. Apoptosis is not frequently detected in KS or PEL tumors
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(Katano, Sato et al. 2001). And importantly in agreement with our results, expression of cleaved
(active) caspase 3 is rarely observed in KS tumors (Ramos da Silva, Bacchi et al. 2007).
CASP3 genetic polymorphism is involved in pathogenesis of cancer (Yan, Li et al. 2013) and
CASP3 downregulation is associating with chemoresistance, metastasis and poor prognosis in breast
cancer and non small cell lung carcinoma (Volm, Mattern et al. 1999, Devarajan, Sahin et al. 2002,
Okouoyo, Herzer et al. 2004). Interestingly cellular miRNAs miR-137 and miR-224 have been
identified to inhibit CASP3 in lung carcinoma cells and miR-137 is inducing cisplatin resistance of
lung adenocarcinoma (Cui, Kim et al. 2015, Su, Ku et al. 2016). Therefore CASP3 inhibition by
KSHV miRNAs miR-K12-1, miR-K12-3 and miR-K12-4-3p could cause chemoresistance of PEL
and KS patients.  Thus we wanted to investigate whether the miRNAs that target caspase 3
expression would contribute to the survival of infected cells by inhibiting apoptosis and providing
protection against the cellular anti-viral response, which usually leads to cell death.
1.3 KSHV miRNAs inhibit apoptosis in KSHV-infected endothelial cells
The effect of KSHV miRNAs on the induction of apoptosis was studied in a KSHV-infected
lymphatic endothelial cell line (K-iLEC) model. The KSHV miRNAs targeting caspase 3 were
silenced as before and apoptosis was induced chemically by treating the cells with etoposide, a
DNA damage and apoptosis-inducing small molecule inhibitor of cellular topoisomerases. The
number of apoptotic cells was determined by immunofluorescence staining of cleaved caspase 3
and by measuring the levels of nicked DNA (a marker of apoptosis) using the TUNEL assay (Fig
8A-B in I). Quantitative analysis after fluorescence imaging revealed 2.3 fold more apoptotic cells
in LNA-miR-K12-1/3/4 treated samples (Fig 8C in I) indicating that there is more apoptosis in
KSHV-infected endothelial cells when miR-K12-1, K12-3 and K12-4-3p are silenced. These
miRNAs can therefore effectively inhibit apoptosis in KSHV-infected endothelial cells.
In summary, this study shows that KSHV miR-K12-1, K12-3 and K12-4-3p inhibit expression of
caspase 3 in B-cells, endothelial cells and in the KSHV-infected PEL cells. Moreover, these
miRNAs inhibit apoptosis of latently infected endothelial cells challenged with etoposide.
KSHV has evolved multiple mechanisms to inhibit apoptosis and, as shown in this study, the virally
encoded miRNAs add another 'weapon' to the viral arsenal against host cell anti-viral mechanisms.
In addition to the miRNA-silencing of CASP3 described here, other studies have shown that KSHV
has other means to inhibit the function of caspases. It has recently been shown that when KSHV-
infected cells were artificially induced to undergo apoptosis, the viral latent protein LANA - which
is very abundant in KSHV-infected cells - was found to be cleaved by caspase 1 and 3. It was
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proposed that LANA can impair apoptosis by acting as a caspase 'decoy' substrate (Davis, Naiman
et al. 2015). Another interesting finding suggests that caspase 3-activated apoptosis could induce
reactivation of KSHV and other herpesviruses (Prasad, Remick et al. 2013). This would suggest that
herpesviruses are able to sense the induction of caspase 3-dependent apoptosis and resume lytic
replication and virion release when apoptosis cannot be inhibited or delayed adequately. Hence, the
inhibition of caspase 3 could serve as an additional mechanism to maintain latent infection.
Consistent with this hypothesis, K12-3 and K12-11 miRNAs were shown to inhibit lytic gene
expression by targeting transcription factors required for the transcription of ORF50, the initiator of
the lytic cascade (Plaisance-Bonstaff, Choi et al. 2014).
Multiple KSHV miRNAs have been shown to target regulators of apoptosis. Tandem array-based
expression screen analysis of KSHV miRNA expressing B-cells and KSHV-infected endothelial
cells revealed that miR-K6, miR-K9 and mir-K10a/b target Bcl-2-associated factor (BCLAF1)
(Ziegelbauer, Sullivan et al. 2009). Moreover, miR-K11 targets SMAD5 and miR-K11 targets
TGFβ type II receptor to inhibit TGFβ signaling and promote cell survival (Lei, Zhu et al. 2012,
Liu, Sun et al. 2012). Recently it has been discovered that KSHV can transform the primary rat
mesenchymal precursor cell line (MM), which has provided an important tool to study mechanisms
of KSHV-induced tumorigenesis (Jones, Ye et al. 2012). These cells were used to study the role of
the KSHV miRNAs in tumorigenesis. In this study, a cluster of 10 viral miRNAs were genetically
removed from the KSHV genome and MM cells were infected with this mutant virus. Importantly,
infection did not induce transformation, but instead induced cell cycle arrest or apoptosis (Moody,
Zhu et al. 2013). This study demonstrates how KSHV miRNAs play a major role in the oncogenesis
of KSHV-induced cancers by deregulating host cell proliferation, apoptosis and cell survival.
2. Targeting cellular anti-apoptotic factors to specifically kill virus-infected cells (II,
unpublished data)
2.1 KSHV-infected cells are resistant to the Bcl-2 inhibitor ABT-263
The cellular anti-apoptotic proteins Bcl-2 and Bcl-xL are overexpressed in many cancers, which is
related to poor prognosis and resistance to chemotherapy treatment (Tsujimoto, Finger et al. 1984,
Raffo, Perlman et al. 1995, Friess, Lu et al. 1998). The same factors are also overexpressed in KS,
and expression of Bcl-2 increases during disease progression (Foreman, Wrone-Smith et al. 1996,
Morris, Gendelman et al. 1996). Hence, targeting cellular anti-apoptotic pathways could be a way to
specifically kill virus-infected cells, thus providing a new antiviral strategy.
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As a proof of principle, we tested a small molecule inhibitor, ABT-263, which is a BH-3 mimetic
drug that binds and inhibits the anti-apoptotic functional portions of Bcl-2, Bcl-xL and Bcl-w. This
inhibition resulted in the induction of apoptosis of cancer cells (Wong 2011, Moldoveanu, Follis et
al. 2014).
Cells infected with several different viruses, including KSHV, were treated with different
concentrations of ABT-263 and cell viability was measured by luciferase-based Cell titer glo assay
(CTG, Promega). The results of this analysis showed that ABT-263 could accelerate cell death of
various cell types infected with influenza A and B, Bunyamwera, Semliki Forest, Sindbis, herpes
simplex 1 and 2, vaccinia and measles (Fig. 2C-D in II). However, the inhibitor did not kill
iSLK.219 cells, a cell line latently infected with a recombinant KSHV ((Myoung and Ganem 2011);
Fig. 2D in II, Figure 6A, no ind)).
To study the effect of ABT-263 on de novo infected cells, we infected SLK cells (the non-infected
parental cell line of iSLK.219 cells) with recombinant KSHV (rKSHV.219, (Vieira and O'Hearn
2004)) and simultaneously with the virus we added the inhibitor to the cells in 3-fold dilutions at 7
different concentrations starting from 10 μM. Cell viability was measured by the CTG assay 24
hours post infection. The dose response curve showed no difference in the cell viability between
non-infected (Mock) and rKSHV.219-infected cells (Figure 5).
Figure 5. ABT-263 inhibitor did not induce cell death of de novo infected SLK cells. Mock or rKSHV.219-infected
SLK cells were treated with indicated concentrations of ABT-263 drug and 24 hours post infection cell viability was
measured to determine the dose response curve.
These results demonstrate that in contrast to the other viruses tested in this study, KSHV-infected
cells do not respond to the Bcl-2 inhibitor, ABT-263. Probably indicating that survival of latent
KSHV infected cells and cell survival upon KSHV infection is not dependent on Bcl-2, Bcl-xL or
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Bcl-w proteins. This could be explained by the viral inhibition of caspase 3 and caspase-8 and thus
apoptosis during latent infection (Figure 8 A-C in I)(Belanger, Gravel et al. 2001, Davis, Naiman et
al. 2015). Another mechanism behind the ABT-263 resistance of the latent KSHV infected cells
could be the viral inhibition of p53 (Rivas, Thlick et al. 2001, Sarek, Kurki et al. 2007, Chen, Hilton
et al. 2010, Baresova, Musilova et al. 2014), since it has been shown that Bcl-xL is binding and
inhibiting p53 (Follis, Chipuk et al. 2013), therefore inhibition of Bcl-xL by ABT-263 could lead
release of p53 and induction of apoptosis, which is probably inhibited by KSHV latent proteins.
2.2 ABT-263 did not induce cell death of the lytic KSHV-infected cells
To test whether ABT-263 treatment would cause cell death of cells undergoing active KSHV lytic
replication, we induced the lytic cycle in iSLK.219 cells with doxycycline and NaB. 24 hour post
induction (hpi) we added the drug as in the earlier experiments followed by monitoring of cell
viability with the CTG assay. ABT-263 did not cause significant cell death during the latent or lytic
phase of KSHV life cycle in iSLK.219 cells (Fig. 6A). The inhibitor was also tested in BC-3 PEL
cells. To induce the lytic cycle of the virus, the cells were treated with TPA 24 hours prior ABT-263
treatment, and cell viability was measured 24 hours later with the CTG assay. As shown in Figure
4B, ABT-263 did not cause cell death of either latent or lytic BC-3 cells.
Figure 6. Dose response curve of non-induced (latent KSHV) and induced (lytic viral cycle) iSLK.219 cells (A) and
DMSO (-TPA) or TPA-induced BC-3 cells (B).
In summary, our data demonstrate that lytic KSHV-infected cells were resistant to the ABT-263
drug, indicating that the viability of KSHV-infected cells is not dependent on the cellular Bcl-2,
Bcl-xL or Bcl-w proteins. Probably the function of anti-apoptotic Bcl-2 proteins is redundant in
lytic KSHV infected cells as KSHV encoded vIRF1 is able to bind and inhibit Bim and Bid during
lytic infection (Choi and Nicholas 2010, Choi, Sandford et al. 2012) and vIAP is inhibiting caspase-
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3 (Wang, Sharp et al. 2002). And furthermore multiple lytic proteins inhibiting p53 mediated
apoptosis (Gwack, Hwang et al. 2001, Katano, Ogawa-Goto et al. 2001, Nakamura, Li et al. 2001,
Seo, Park et al. 2001, Chudasama, Konrad et al. 2015). The most promising viral candidate behind
the ABT-263 resistance of lytic KSHV infected cells is the viral homolog of Bcl-2 protein: ORF16
(vBcl-2)  binding multiple pro-apoptotic BH-3 proteins (Sarid, Sato et al. 1997, Huang, Petros et al.
2002, Loh, Huang et al. 2005, Flanagan and Letai 2008). To investigate this possibility further, we
monitored the kinetics of expression of the ORF16 gene at different stages of the lytic cycle that
was induced in iSLK.219 or BC-3 cells by the addition of doxycycline/NaB or TPA, respectively.
RNA  samples  were  collected  at  0,  4,  8,  12,  24,  30  and  48  hours  post  induction  (hpi)  and  the
expression of ORF16 was analyzed by qRT-PCR. This analysis revealed a fast and robust
upregulation of ORF16 expression in iSLK.219 cells at 4 h after reactivation, followed by a linear
increase until 30 h (Fig. 7A). In BC-3 cells, the expression of ORF16 was detectable at 4 hpi and it
increased linearly during the time course of TPA treatment (Fig. 7B).
Figure 7. Expression of ORF16 (vBcl-2) in the KSHV-infected lytic-induced cells. A) qRT-PCR analysis of
iSLK.219 cells induced for lytic cycle with doxycycline and NaB treatment prior to RNA extraction at indicated time
points. B) qRT-PCR analysis of BC-3 cells induced with TPA treatment at indicated time points.
These data indicate that KSHV-infected cells efficiently express the product of the ORF16 gene
both in the early and late phases of the lytic cycle. Expression of ORF16 coexists with the ABT-263
treatment  as  it  was  administered  to  cells  24  hours  post  reactivation  thus  it  could  explain  the
resistance of lytic iSLK.219 and BC-3 cells on ABT-263 treatment (Figure 6). Interestingly, a
recently published study of vBcl-2 protein structure revealed that the BH3 binding groove of the
viral protein is structurally and functionally similar to another cellular anti-apoptotic protein, Mcl-1
(Foight and Keating 2015). Moreover expression of Mcl-1 have been identified to be mediating
resistance of breast cancer, NHL and multiple myeloma cells to Bcl-2/Bcl-xL/Bcl-w inhibitors
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(Phillips, Xiao et al. 2015, Xiao, Nimmer et al. 2015, Punnoose, Leverson et al. 2016). Resistance
of lytic KSHV infected cells to ABT-263 treatment could be explained by anti-apoptotic function of
vBcl-2 and its resemblance with Mcl-1 and the possibility that ABT-263 could not bind vBcl-2 and
inhibit its function. Accordingly, we next tested if inhibitor of Mcl-1, Obatoclax, could induce cell
death of KSHV infected cells.
2.3 Obatoclax induces cell death in the lytic KSHV-infected cells
To test whether Obatoclax could cause cell death of the latent and lytic KSHV-infected cells, the
lytic cycle in iSLK.219 cells were induced with doxycycline and NaB.  At 24 hpi cells were treated
with the same concentrations as in Figures 5 and 6 and cell viability was monitored with the CTG
assay. Obatoclax treatment did not induce a remarkable amount of cell death in the latent iSLK.219
cells (Figure 8, no ind.). As for the lytic iSLK.219 cells, Obatoclax treatment induced significant
cell death at the lower concentrations of 123-370 nM (Figure 8, ind.).
Figure 8. Obatoclax induces cell death in lytic KSHV-infected cells. iSLK.219 cells were induced for lytic cycle
with doxycycline and NaB and 24 hpi cells were treated with indicated doses of Obatoclax and cell viability was
analyzed with CTG assay. No in= cells treated with DMSO prior Obatoclax; ind=cells treated with doxycycline and
NaB prior Obatoclax.
These results indicate that Obatoclax is able to specifically target and kill the lytic KSHV-infected
cells. Importantly, a recent study has identified that Obatoclax is able to also kill latently infected
PEL cells but that this effect requires both higher concentrations and a longer treatment time of 48-
72 hrs (Nayar, Lu et al. 2013), indicating that cells infected with lytic virus are more sensitive to the
Obatoclax treatment. These findings indicate that the survival of KSHV-infected cells may be
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dependent on the Mcl-1 protein. This is further supported by a recent study in which the
dependency of KSHV-infected cells on the individual anti-apoptotic Bcl-2 proteins was screened
with a BH3 profiling method which revealed that survival of latent PEL cells is indeed dependent
on Mcl-1 and vBcl-2 (Cojohari, Burrer et al. 2015). Interestingly this study demonstrated that the
ABT-737 inhibitor targeting Bcl-2 and Bcl-XL or the MIM1 inhibitor specifically targeting only
Mcl-1 could not kill the latently infected PEL cells (Cojohari, Burrer et al. 2015). Hence it appears
that KSHV simultaneously utilizes both Mcl-1 and vBcl-2 to ensure its survival. Therefore the pan
Bcl-2 inhibitor like Obatoclax inhibiting in addition to Mcl-1 also Bcl-2, Bcl-xL and Bcl-w, could
offer a new anti-viral drug candidate to treat KSHV-associated cancers. To study potential anti-viral
effect of Obatoclax further, it is important to address can Obatoclax inhibit reactivation and release
of viral progeny. Also detailed mechanism of Mcl-1 in lytic cycle of KSHV infection should be
addressed further.
Results with IAV mouse model indicated that when treated with ABT-263 drug mice had
significantly lower survival rate than mock treated animals (Figure 7 A in II) and furthermore ABT-
263 induced imbalanced cytokine production of IAV infected mice (7 E-F in II). Causing potential
thread to ABT-263 treated cancer patients with underlying or apparent viral infection. KSHV
infection is associated with KICS which has similar symptoms as seen in ABT-263 treated IAV
mice; as these patients have elevated cytokine levels and higher viral loads (Uldrick, Wang et al.
2010, Polizzotto, Uldrick et al. 2012), thus it is important to keep in mind that treatment of patients
with KSHV associated cancer could have a higher risk to develop KICS. Therefore it is important to
test can Obatoclax and other Bcl-2 inhibitors induce lytic cycle of KSHV infected cells and further
test these inhibitors in animal models like PEL xenograft mice.
The  research  on  the  host  cell  mechanisms utilized  by  tumor  viruses  enables  to  discover  potential
new anti-viral drugs towards KSHV and its associated diseases. The KSHV lytic cycle has an
instrumental role in the emergence and progression of KS (Whitby, Howard et al. 1995, Moore,
Kingsley et al. 1996, Keller, Zago et al. 2001, Cannon, Dollard et al. 2003, Engels, Biggar et al.
2003). Therefore it is highly important to study the cellular mechanisms that are necessary for the
viral lytic program.
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3. KSHV utilizes the p53 stress response to induce a G2/M cell cycle checkpoint for efficient
lytic replication (III)
3.1 siRNA screen identifies MDM2 as a novel regulator of KSHV reactivation
To discover new host cell regulators of KSHV reactivation, we performed an RNAi screen using a
custom-made library of siRNA oligos targeting 615 different human epigenetic factors and their
regulators. In this screen, we used an SLK cell line (Herndier, Werner et al. 1994, Sturzl, Gaus et al.
2013) infected with a recombinant reporter KSHV (rKSHV.219) (Vieira and O'Hearn 2004) as a
model system for reactivation. The rKSHV.219 virus contains, in addition to all the KSHV genes, a
gene coding for green fluorescent protein (GFP), the expression of which is under the control of a
cellular constitutively active promoter (EF-1α), and a gene coding for red fluorescent protein (RFP),
the  expression  of  which   is  under  control  of  the  viral  lytic  PAN  promoter  (Vieira  and  O'Hearn
2004). With this reporter virus the latently infected cells can be visualized by expression of GFP
and the lytic replication-induced cells can be monitored by the expression of RFP. The screen was
done by using a cell-spot microarray technique as detailed in the materials methods section (CSMA;
(Rantala, Makela et al. 2011). A schematic of the siRNA screen workflow is depicted in Fig. S1A
of publication III. The screen identified 20 novel cellular factors that increased the efficiency of
KSHV reactivation when depleted. One of the strongest hits was MDM2, an ubiquitin E3 ligase and
master regulator of p53 protein stability (Fig. S1 B in III). Using additional, different siRNA oligos
than those used in the screen to target MDM2, this hit was validated in the rKSHV.219-infected
SLK cell clone (iSLK.219), in which KSHV reactivation can be induced by doxycycline treatment
(Myoung and Ganem 2011). These validation experiments revealed that the silencing of MDM2 led
to a 3-fold higher RFP expression in iSLK.219 cells, indicating increased reactivation (Fig. 1 A-B
in III).
3.2 Knockdown of MDM2 enhances KSHV reactivation
To validate the finding from the siRNA screen using a biologically more relevant cell line, we
depleted MDM2 mRNA expression in PEL cells (BC-3) by using lentivirus-mediated short hairpin
RNA  (shRNA)  treatments  (sh-MDM2  and  control  shRNA;  sh-Scr).  To  determine  the  effect  of
MDM2 depletion on spontaneous reactivation we measured the relative amount of lytic transcripts
by qPCR. This analysis revealed that MDM2 depletion led to increased mRNA levels of the lytic
transcripts expressed in the immediate early- (ORF50), delayed early- (ORF57 and vGPCR) and
late- (K8.1) lytic replication phases (Fig. 1C in III). To examine the effect of MDM2 silencing on
maximal reactivation, we induced reactivation with TPA treatment and measured lytic gene
expression at different phases of the reactivation cascade (4, 8 and 48h). Importantly, MDM2
RESULTS AND DISCUSSION
57
depletion enhanced expression of all the measured lytic genes after 4 and 8 hours of TPA induction
(Fig  1D in  III),  while  at  the  later  time point  (48  h)  only  the  expression  of  K8.1  was  significantly
increased (Fig 1D in III).
Altogether these results demonstrate that knockdown of MDM2 enhances the expression of lytic
genes in both non-induced and TPA-induced PEL cells, thus supporting that MDM2 regulates both
the spontaneous and chemically-induced KSHV reactivation. Importantly, similar results have been
obtained with adenovirus, another DNA virus, by showing that knockout of MDM2 and MDM4
leads to increased viral gene expression (Yang, Zheng et al. 2012). Interestingly, previous results
also indicate that the MDM2 antagonist Nutlin-3 induces lytic reactivation of KSHV-infected
endothelial cells, strengthening our hypothesis that MDM2 is a negative regulator of KSHV
reactivation (Ye, Lattif et al. 2012). MDM2 is highly expressed in the PEL tumors in comparison to
other B-cell lymphomas (Petre, Sin et al. 2007, Sarek, Kurki et al. 2007). Moreover, our group and
others have demonstrated that during the latency phase, LANA forms a ternary complex with p53
and MDM2 and that this complex is disrupted by Nutlin-3 treatment (Sarek, Kurki et al. 2007,
Chen, Hilton et al. 2010). These findings therefore suggest that MDM2 could have an important
role in the maintenance of latent infection, probably by sequestration of p53 together with LANA.
Our earlier studies indicate that Nutlin-3 treatment induces p53-mediated apoptosis of latently
infected PEL cells but, interestingly, cells undergoing lytic infection were refractory to the cell
killing  effect  of  Nutlin-3  (Sarek,  Kurki  et  al.  2007,  Sarek,  Ma  et  al.  2013).  This  implies  that  the
restored p53 somehow prevents the cells from undergoing apoptosis and instead favors the cells
infected with the lytic KSHV. Therefore, we wanted to examine the role of this tumor suppressor in
KSHV reactivation in more detail.
3.3 Viral reactivation leads to a p53 response in PEL cells
To comprehensively study the role of p53 in KSHV reactivation, we analyzed the occupancy of p53
on the infected host cell chromatin and viral genomes with ChIP sequencing (ChIP-seq) analysis of
reactivation-induced, TPA-treated BC-3 cells. In this assay, Nutlin-3-treated cells were used as a
positive  control.  Analysis  of  the  input  samples  showed  p53  stabilization  at  24  h  upon  TPA
treatment and a strong induction of p53 in the positive control sample (Fig. 2D in III). To our
surprise, the ChIP-seq analysis showed no p53 binding on the KSHV genome, indicating that p53 is
not functioning through binding to the viral genome but rather is activated by the virus and
regulates the host  cell  gene expression (Fig.  2 B in III).  Analysis of p53 binding sites on the host
cell genome demonstrated that a partial p53 response occurred upon TPA-induced reactivation (Fig.
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S3A  in  III).  Gene  Ontology  (GO)  analysis  of  these  p53  binding  sites  revealed  genes  related  to
cellular processes such as p53 regulation (MDM2), cell cycle arrest (CDKN1A), DNA repair
(p53R2) and apoptosis (PAG608) (Fig. 2A and S3C in III).  Next, we decided to focus on the cell
cycle arrest function of the p53 response and validate the induction of CDKN1A gene expression by
immunoblotting its gene product, p21Cip-1,  from  the  24h  TPA  and  8h  Nutlin-3-treated  BC-3  cells
(Lane 2 in Fig. 2D in III). Importantly, we could detect an equally strong p21Cip-1response in both
TPA and Nutlin-3 treated cells (Lane 2 in Fig. 2D in III). Moreover, we found a potent p21Cip-1
response in both the NaB-induced BC-3 and TPA/Dox or NaB/Dox-induced iSLK.219 cells (Fig.
2E in III), indicating that the p21Cip-1 response is not limited to  PEL cells but also occurs in other
infection models upon KSHV reactivation.
In summary, our results demonstrate that KSHV reactivation induces both a p53 response and
p21Cip-1 upregulation in PEL and iSLK.219 cells. This is a novel and unexpected finding since
earlier studies suggest that KSHV reactivation would inhibit p53 function (Park, Seo et al. 2000,
Gwack, Hwang et al. 2001, Nakamura, Li et al. 2001, Lee, Toth et al. 2009, Chudasama, Konrad et
al. 2015). One explanation for our contradictory finding is that some of these referenced studies
have been performed only with artificial overexpression methods (Gwack, Hwang et al. 2001,
Nakamura, Li et al. 2001), whereas in our results we showed a p53 response in two independent
lytic  KSHV-infected  cell  lines  (Fig  2E  in  III).   On  the  other  hand,  it  could  be  possible  that  p53
activity is carefully regulated during the lytic cycle so that in the early phase of reactivation, p53 is
required for efficient replication, and in the later phase it needs to be inhibited by lytic proteins in
order to prevent premature apoptosis. Indeed, there are indications that this is the case, since K8
was  shown  to  interact  with  p53  in  PEL  cells  48  hours  post  TPA  induction.  Moreover,  late  lytic
structural proteins ORF22, ORF25 and ORF64 were identified to inhibit p53-mediated
transactivation of apoptotic genes (Park, Seo et al. 2000, Chudasama, Konrad et al. 2015).
Therefore we wanted to further address the biological consequences of the p53 response at the early
phase of lytic replication.
3.4 p53 is required at the early phase of the reactivation for efficient lytic replication
To study the role of p53 in lytic replication we silenced p53 expression prior to the induction of
reactivation. To this end, we first depleted p53 expression from iSLK.219 cells with lentivirus-
mediated shRNA for 48 hours and thereafter induced the cells for reactivation with
TPA/Doxycycline (TPA/Dox) treatment. Reactivation was measured by RFP expression with
automated fluorescence microscopy. This analysis showed that knockdown of p53 caused a
remarkable decrease in the amount of cells undergoing lytic reactivation (Fig 3C-D in III). This was
RESULTS AND DISCUSSION
59
further  supported  by  a  qPCR  analysis  for  the  expression  of  a  set  of  lytic  genes  which  showed
impaired induction of lytic gene expression in p53-depleted BC-3 cells induced for reactivation by
TPA  or  NaB  treatment  (Fig  S4  C-D  in  III).  To  examine  how  stabilized  p53  would  influence  the
early steps of reactivation, we pre-treated the iSLK.219 cells with Nutlin-3 for 18 h, followed by
TPA/Dox induction of reactivation for 24 h, and quantified RFP expression with automated
fluorescent microscopy. Intriguingly, although Nutlin-3 treatment normally induces a strong p53
stabilization and G1 cell growth arrest in non-reactivated cells (Fig. S4 A-B and 6 C in III), under
these  conditions  the  cells  did  not  arrest  at  G1,  but  rather  progressed  to  G2  (Fig.  6  C  in  III).
Importantly, we also demonstrated that Nutlin-3 synergizes with the TPA/Dox and Dox treatments
and enhances the reactivation capacity of iSLK.219 cells (Fig 3A-B in III).
Altogether, our studies revealed a distinct p53 response in lytic PEL cells, and strikingly, we found
that efficient KSHV reactivation requires intact p53. Interestingly, human herpesviruses HSV-1,
CMV,  EBV and HIV-1  can  utilize  p53  to  ensure  efficient  replication  (Casavant,  Luo et  al.  2006,
Pauls, Senserrich et al. 2006, Chang, Lo et al. 2008, Maruzuru, Fujii et al. 2013). However, the
mechanisms used by these viruses appear different from KSHV as p53 has been reported to bind to
viral lytic promoters. Therefore, it was somewhat surprising that we could not detect any p53
binding on the virus genome, a result which indicates that p53 does not participate directly in viral
transcription (Fig. 2 B in III), and suggests that KSHV perhaps utilizes some of the p53 response
genes to secure efficient replication.
3.5 p53 is required to induce p21Cip-1-mediated G2/M cell cycle arrest upon KSHV reactivation
We next focused on one of the best-known p53 target genes, p21Cip-1, that we had already identified
by ChIP-Seq and had found to be induced in the reactivated BC-3 and iSLK.219 cells (Fig. 2E in
III). To address the requirement of p21Cip-1 in KSHV reactivation we silenced its expression by
RNAi and showed that p21Cip-1 was required for efficient reactivation (Fig 3E-F in III). As p21Cip-1
is a Cdk inhibitor and can cause cell cycle arrest at G1 and G2 phases (el-Deiry, Tokino et al. 1993,
Harper, Adami et al. 1993) we wanted to determine whether KSHV reactivation would lead to cell
cycle arrest. For these studies we developed an automated, high-content image-based cell cycle
analysis method (Fig. 5A and Fig. S6 in III). Cell cycle status of the cells in the lytic infection phase
was investigated by indirect immunofluorescence (IF) using an antibody recognizing histone 3
phosphorylated on serine 10 (pH3 S10, Fig. 5A in III). Interestingly, this analysis revealed that the
lytic iSLK.219 cells were arrested at the G2 phase of the cell cycle (Fig. 5 C-D in III). Depletion of
p21Cip-1 from iSLK.219 cells prior to reactivation decreased the amount of cells in G2 arrest
compared to si-Ctrl-transfected cells and increased the proportion of cells in M-phase (Fig 5 G in
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III).  As depletion of p21Cip-1 also significantly decreased viral reactivation (Fig 3E-F in III), these
results indicate that KSHV requires p21Cip-1 in order to arrest the reactivated cells at G2, which is
necessary for efficient lytic replication.
Induction of G2/M arrest has also been recognized with other herpesviruses.  These studies show
that a HHV-6B-encoded protein, DR6, induces a p53-independent G2 arrest and that an EBV-
encoded protein, LMP-1, induces a G2 arrest by upregulating 14-3-3 sigma and reprimo proteins
which inactivate the Ckd1/CyclinB complex (Yeo, Mohidin et al. 2012, Schleimann, Hoberg et al.
2014). Thus our discovery shows for the first time that KSHV lytic infection also leads to the
induction of G2/M arrest and that KSHV reactivation requires p53-dependent p21Cip-1 activity  to
induce the G2 arrest, which probably functions to secure sufficient time to complete the viral lytic
replication. This also explains why, unlike in many other human cancers, p53 is rarely mutated in
the KSHV-associated malignancies (Katano, Sato et al. 2001).
So what is the viral mechanism behind the reactivation induced, p21Cip-1 mediated G2/M arrest?
Interestingly v-cyclin can bypass a G1 arrest when complexed with CDK6 by phosphorylating
p21Cip-1 and preventing its binding to CDK2 (Jarviluoma, Child et al. 2006). Since v-cyclin is not
only expressed during the latent infection and its expression is actually increased upon lytic
reactivation (Arias, Weisburd et al. 2014), it could be the mechanism behind the inactivation of the
G1 checkpoint during lytic cycle. Importantly it has been shown that murine gammaherpesvirus 68
(γMHV-68) encoded v-cyclin is vital for lytic reactivation (van Dyk, Virgin et al. 2000). Therefore
it remains to be seen if the KSHV v-cyclin also has a role in KSHV reactivation.
Altogether results of this thesis project provide new insights as to how KSHV utilizes the p53 stress
response in lytic reactivation. Importantly this finding could be one of the mechanisms how lytic
KSHV infected cells develop drug resistance. Moreover, as previously shown in the case of Nutlin-
3,  the  restoration  of  p53  could  not  induce  apoptosis  or  cell  cycle  arrest  of  in  the  lytic  PEL  cells
(Sarek, Kurki et al. 2007, Sarek, Ma et al. 2013). Therefore, the results in this thesis that
demonstrate the reactivation induced bypass of Nutlin-3 induced G1 arrest (Fig 6 C in III) provide a
mechanism for the inability of Nutlin-3 to arrest or kill PEL cells. This is an important finding when
considering the treatment modalities of KSHV induced cancers and could be one of the mechanisms
behind drug resistance of the lytic KSHV infected cells.
Another example on possible drug resistance of lytic KSHV infected cells is the study with c-MET
inhibitor PF-2341066. Although c-MET inhibitor was shown to induce G2/M cell cycle arrest and
DNA damage mediated apoptosis of PEL cells, this inhibitor was also inducing activation of p53
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and minor lytic reactivation (Dai, Trillo-Tinoco et al. 2015). Therefore it could be possible that c-
MET inhibition is activating a p21Cip-1 mediated G2/M arrest which supports KSHV infected cells
undergoing lytic replication and thus promotes cancer progression and could cause drug resistance
during longer treatment periods.
p21Cip-1 is pleiotropic protein as it is in the other hand inducing cell cycle arrest and apoptosis and
thus preventing proliferation of cancer cells and acting as tumor suppressor, but in the other hand it
can inhibit apoptosis by binding and inhibiting caspase-3, apoptosis signal-regulating kinase 1
(ASK1) and JNK and acting as oncogene (Asada, Yamada et al. 1999, Abbas and Dutta 2009,
Cmielova and Rezacova 2011). P21Cip-1 is overexpressed in multiple cancers and is correlating with
poor prognosis (Weiss 2003, Weiss, Borowsky et al. 2007, Abbas and Dutta 2009). Degree of
p21Cip-1 function  depends  on  the  extent  of  the  DNA  damage,  as  in  the  case  of  low  level  DNA
damage p21Cip-1 expression is increased inducing cell cycle arrest and inhibition of apoptosis and in
the case of massive DNA damage p21Cip-1 expression is decreased causing induction of apoptosis
(Cmielova and Rezacova 2011). Interestingly recent study showed that prolonged p21Cip-1
expression in p53-deficient cells caused replication stress and error-prone DNA repair could have
prognostic and therapeutic implications for cancer (Galanos, Vougas et al. 2016). A subset of p53-
deficient cancer cells and tumours overexpressed nuclear p21Cip-1 and further studies with p53-
deficient cell line with inducible p21Cip-1 expression revealed that prolonged p21Cip-1 expression
caused replication stress and error-prone DNA repair and resulted in development of chromosomal
instability (Galanos, Vougas et al. 2016). P21Cip-1 inhibition could be explored as an anti-cancer
approach and importantly studies with small molecule inhibitors of p21Cip-1 have been revealed their
potential in treatment of chemo-resistant cancers (Park, Wang et al. 2008, Inoue, Hwang et al. 2011,
Wettersten, Hee Hwang et al. 2013). It would be important to study the expression level of p21Cip-1
in KSHV associated cancers and the possibilities to inhibit the function of p21Cip-1 and target lytic
KSHV infected cells and thus inhibit release of viral progeny. Treatment of PEL is challenging and
patients often develop resistance against chemotherapy thus inhibition of p21Cip-1 could offer a
therapeutic modality in treatment of PELp21Cip-1
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4. Characterization of the protein-protein interactome of v-cyclin and host cell proteins
V-cyclin functions through interaction with cellular proteins like CDKs and most of the identified
v-cyclin interactions are occurring via the CDK6 interaction. In the earlier studies v-cyclin
interacting proteins have been identified either with transient, exogenous co-expression or
immunoprecipitates from KSHV infected cell lines (Godden-Kent, Talbot et al. 1997, Li, Lee et al.
1997, Platt, Cannell et al. 2000, Chang and Li 2008). To reveal comprehensive interactome of v-
cyclin and cellular proteins a tetracycline inducible isogenic v-cyclin expressing human cell line
was generated.
4.1 Generation of tetracycline inducible isogenic v-cyclin expressing human cell line
To generate v-cyclin expressing cell line pcDNA5/FRT/TO/v-cyclin/SH/GW expression plasmids
and pOG44 plasmid expressing Flippase (Flp) recombinase enzyme were co-transfected into
HEK293 Flp-In cells (Invitrogen). Co-transfection induced Flp mediated homologous
recombination between FRT sites of the cellular genome and expression plasmid (Figure 9A).
Hygromycin resistance gene enables antibiotic selection of the isogenic v-cyclin cell clones. In
these cells only one copy of v-cyclin gene is integrated into the host cell genome (Glatter, Wepf et
al. 2009) and v-cyclin expression is repressed by tet-operator 2 (TetO2) that represses the promoter
activity in the absence of tetracycline (Hillen and Berens 1994). This enables to adjust the v-cyclin
expression to physiological expression levels and to avoid p53 induced growth arrest by continuous
overexpression of v-cyclin. Cell lines generated in this study are named 293FlpIn-vcyc1 (vcyc1),
293FlpIn-vcyc2 (vcyc2) and 293FlpIn-Ctrl (Ctrl).
Next optimal tetracycline concentration was titrated to obtain similar expression level of v-cyclin as
in KSHV infected cells. Thus tetracycline was added 0, 8, 40, 200 and 1000 ng/ml to vcyc1 and
vcyc2 cells and incubated 24 h prior the lysis. As a control whole cell lysates from non-tetracycline
induced Ctrl cells, KSHV negative lymphoblastoid cell line (CZE) and KSHV positive PEL cell
line (BC-3) were prepared. Lysate samples were Western Blotted using antibodies against v-cyclin,
Hemagglutinin (HA) and tubulin. As illustrated in Figure 9B Ctrl and CZE cells did not express v-
cyclin  or  HA  and  as  expected  BC-3  cells  expressed  wild  type  v-cyclin,  which,  as  expected,  was
migrating faster than the Strep- and HA-tagged v-cyclin of vcyc1 and vcyc2 cells. Linear increase
in v-cyclin expression along with ascending concentration of tetracycline of the vcyc1 and vcyc2
cell  lines  was  visible  in  both  v-cyclin  and  HA  blots  (Figure  9B).  Expression  of  v-cyclin  was
stronger in the vcyc1 cells than in the vcyc2 cells (Figure 9B v-cyclin and HA blots). Induction of
the vcyc1 cells with 200 ng/ml of tetracycline resulted in similar v-cyclin expression level than in
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BC-3 cells thus resembling the expression level in latently infected cells (Figure 9B). Expression of
v-cyclin was also confirmed at mRNA level from the 200 ng/ml tetracycline induced vcyc1 and
vcyc2 cell lines with the qPCR method (Figure 9C). V-cyclin expression was strongly induced with
tetracycline and as seen at the protein level, v-cyclin expression was stronger in the vcyc1 cells than
in the vcyc2 cells (Fiure 9C).
Figure 9 Generation of the tetracycline inducible, isogenic v-cyclin expressing human cell line. Schematic
illustration of the generation of the 293FlpIn-vcyc1 (vcyc1), 293FlpIn-vcyc2 (vcyc2) and 293FlpIn-Ctrl (Ctrl) cell lines
(A). Western Blot analysis using antibodies to v-cyclin, HA and Tubulin of the 293FlpIn-Ctrl (Ctr), KSHV negative
lymphoblastoid cell line (CZE) and KSHV positive PEL cell line (BC-3) and  the tetracycline induced 293FlpIn-vcyc1
(vcyc1) and 293FlpIn-vcyc2 (vcyc2) cell lines. Specific tubulin band marked with asterisk (B). Quantified mRNA level
of expressed ORF72 (v-cyclin) from 200 ng/ml tetracycline induced Ctrl, vcyc1 and vcyc2 cell lines with qPCR method
(C).
Although 200 ng/ml tetracycline induction led to expression of v-cyclin at similar levels as in the
naturally infected cells, 1000 ng/ml concentration was decided to apply for the affinity purification
to reach sufficient expression level to purify the bait protein efficiently.
4.2 Affinity purification of v-cyclin and its binding proteins
To discover the v-cyclin protein-protein interaction network the vcyc1, vcyc2 and ctrl cells were
induced 24h with 1000 ng/ml tetracycline and whole cell lysates were collected and subjected to
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affinity purification (AP) utilizing the N-terminal strep-tag II peptide, which was immobilized to
resin carrying streptavidin (Strep-Tactin) (Figure 10A).
Samples were collected according to the AP procedure and resolved with SDS-PAGE and proteins
were detected with silver staining to validate the quality of the purification procedure (Figure 10B.)
Whole cell lysate sample (Lysate) showing the composition of the expressed proteins in the ctrl,
vcyc1 and vcyc2 cells, flow through sample (Flowthrough) showing unbound proteins washed out
from the Step-Tactin column and Strep-tag AP eluate sample (Eluate) showing purified proteins
(Figure 10B). Silver gel shows that the bait protein was efficiently purified from the vcyc1 and
vcyc2 lysates with Strep-tag AP (Eluate sample in Figure 10B, bait marked with asterisk).
Abundance of the bait protein was higher in the vcyc1 eluate than in the vcyc2 eluate, which is in
accordance with the result of v-cyclin and HA blotting in Figure 9B.
Purification of the bait protein was confirmed also with Western Blotting of the lysates, flow
through and the AP samples using an HA antibody (Figure 10C). The HA blot shows that ctrl lysate
did not contain v-cyclin whereas from the vcyc1 and vcyc2 lysates v-cyclin was detected (Figure
10C, Lysate column). Importantly, from the flow through samples only a small amount of unbound
bait protein was detected, indicating efficient binding of the bait protein to Strep-Tactin resin
(Figure 10C, Flowthrough column).  Eluate samples of vcyc1 and vcyc2 gave a strong HA signal,
which was clearly stronger than in the lysate samples, indicating successful enrichment of the bait
protein in the Strep-tag-AP (Figure 10C, Eluate column). Repeatedly, the vcyc1 eluate contained
higher amount of v-cyclin bait protein than the vcyc2 eluate (Figure 10C, Eluate column).
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Figure 10 Strep-tag affinity purification (AP) of the v-cyclin bait and the associating proteins. Schematic
illustration of the strep-tag AP of the tetracycline induced Ctrl, vcyc1 and vcyc2 whole cell lysates (A). Validation of
the AP process with silver gel. Whole cell lysates (Lysate), Flowthrough samples washed out from the Step-Tactin
column (Flowthrough) and final eluates from the Strep-Tactin column of Ctrl, vcyc1 and vcyc2 were resolved with
SDS-PAGE gel and proteins were detected by silver staining. Bait protein is marked with an asterisk. (B). Purification
of the bait protein was confirmed also with Western Blotting (WB) of the lysates, Flowthrough and the AP eluate
samples using an HA antibody (C).
Double tag fusion protein generated in this study enables to utilize the tandem affinity purification
(TAP) method. Although initially TAP was performed the bait recovery was not found sufficient
(data not shown). TAP is more suitable for detection of stable protein-protein interactions (Chen
and Gingras 2007) and as the v-cyclin mostly binds to its kinase partner(s), the other associating
proteins are often only transiently bound, typically upon phosphorylation of a substrate.  Therefore,
the Strep-tag AP suited better for isolation of these protein complexes. Problem with the Strep-tag
AP if compared to TAP is the higher probability of non-specific interactions. To identify high
confidence protein interactome the Ctrl cell line and contaminant database compiled from 300
individual affinity purification pull down experiments were used to filter out non-specific
interactions.
4.3 Identification of the v-cyclin interacting proteins by AP LC-MS/MS
To pursue v-cyclin interacting proteins, purified protein complexes from the Strep-tag-AP of ctrl,
vcyc1 and vcyc2 cell lines were analyzed with liquid chromatography mass spectrometry (LC-
RESULTS AND DISCUSSION
66
MS/MS). Strep-tag-AP coupled to LC-MS/MS analysis was repeated twice. List of the v-cyclin
interacting proteins is presented in table 4. Analysis of LC-MS/MS data revealed 14 v-cyclin
interacting proteins of which six have been identified earlier (Table 4, known, marked with grey
colour) and eight are previously unknown interactions (Table 4, novel, marked with yellow colour).
Amongst the known interaction partners were three Cdks: Cdk2, Cdk5 and Cdk6 and three CDKIs:
p16INK4A, p18INK4C and p27Kip1(Godden-Kent, Talbot et al. 1997, Li, Lee et al. 1997, Mann, Child et
al. 1999, Jeffrey, Tong et al. 2000, Platt, Cannell et al. 2000, Kaldis, Ojala et al. 2001, Jarviluoma,
Koopal et al. 2004). Cdk6 was detected with high peptide counts, which is in accordance with the
current knowledge that v-cyclin primarily interacts with Cdk6 (Godden-Kent et. al 1997, Li et al.
1997, Meyerson & Harlow 1994, Ojala et al. 1999). Surprisingly, another well documented v-cyclin
interaction partner Cdk4 was not amongst the peptides obtained from LC-MS/MS analysis, which
could  be  due  to  a  weak  interaction  of  the  v-cyclin  with  Cdk4  (Li,  Lee  et  al.  1997).  Additionally
p16INK4A and p18INK4C have been reported to inhibit complex formation of v-cyclin and Cdk6 in
HEK293 cells and in vitro (Jeffrey, Tong et al. 2000, Yoshioka, Noguchi et al. 2010). And as
p16INK4A and p18INK4C were both pulled down with the v-cyclin bait it is possible that these CDKIs
could inhibit the formation of v-cyclin/Cdk4 complex and thus this interaction was not detected
from the LC-MS/MS analysis.
Amongst the novel v-cyclin interacting proteins were two Cdks: Cdk1 and Cdk7, a deubiquitinating
enzyme BRCA1 associated protein-1 (Bap1), a core chromatin histone H4, an anti-apoptotic
paternally expressed gene 10 (Peg10), a nucleolar rRNA regulator and p53 activator/NF-κB
repressor Myb-binding protein 1A (Mybbp1A), X-chromosome linked homologues of ubiquitin
specific peptidase 9 protein (Usp9Y/X) and E3 ubiquitin ligase S-phase kinase associated protein 2
(Skp2) (Table 4). As Skp2 is targeting p27Kip1 for ubiquitination and degradation (Nakayama,
Nagahama et al. 2000), it is likely that it was pulled down together with the v-cyclin/Cdk6/p27Kip1
complex and thus further validations of the Skp2 and v-cyclin interaction were not carried out in
this study. However, validation of 6 other novel v-cyclin interacting partners was further pursued.
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Table 4. List of v-cyclin interacting proteins determined by AP coupled LC-MS/MS analysis. Novel v-cyclin
interacting proteins marked with yellow colour and known v-cyclin interacting proteins marked with grey colour.
Protein Description Novelty
Bap1 BRCA1 associated protein-1
Novel
Cdk1 Cyclin-dependent kinase 1
Cdk7 Cyclin-dependent kinase 7
H4 Histone H4
Mybbp1A Myb-binding protein 1A
Peg10 Paternally expressed gene 10
Skp2 S-phase kinase-associated protein 2
Usp9Y/X Ubiquitin specific peptidase 9, Y and X-linked
Cdk2 Cyclin-dependent kinase 2
Known
Cdk5 Cyclin-dependent kinase 5
Cdk6 Cyclin-dependent kinase 6
p16INK4A Cyclin-dependent kinase inhibitor 2A
p18INK4C Cyclin-dependent kinase 4 inhibitor C
p27Kip1 Cyclin-dependent kinase inhibitor 1B
4.4 Validation of novel v-cyclin interacting proteins by Western Blot
To validate the novel v-cyclin interacting proteins obtained from LC-MS/MS analysis lysates and
the AP eluates of ctrl, vcyc1 and vcyc2 cell lines were Western Blotted with antibodies against
endogenous Cdk1, Cdk7, Bap1, Histone H4, Mybbp1A, Usp9Y and Peg10. Endogenous protein
levels of the analysed proteins were detected equally high from the ctrl, vcyc1 and vcyc2 cell lines,
whereas Peg10 was detected at low levels and the vcyc1 and vcyc2 cells had higher expression
levels than the ctrl cells (Figure 11, lysate samples). Interestingly Cdk1 was detected as a strong
double band whereas Cdk7 displayed a strong and specific single band in the vcyc1 and vcyc2 AP-
eluates (Figure 11, AP-Eluate samples). Bap1 was detected at low levels in the vcyc1 and vcyc2
AP-eluates. Histone H4, Mybbp1A, Usp9Y and Peg10 were not detected from the AP-eluate
samples even after overnight exposure of the blot. Higher expression of the v-cyclin bait in the
vcyc1 cells resulted in more efficient pull down of the validated interaction partners and importantly
AP of the the ctrl did not pull down any of the validated proteins (Figure 11, Cdk1, Cdk7 and  Bap1
blots of AP-Eluate samples). Thus interaction of v-cyclin and Cdk1, Cdk7 and Bap1 were
confirmed by WB.
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Figure 11 Western Blot validation of novel v-cyclin interacting proteins. To validate the novel v-cyclin interacting
proteins obtained from LC-MS/MS analysis lysates and AP eluates of ctrl, vcyc1 and vcyc2 cell lines were Western
Blotted with antibodies against endogenous Cdk1, Cdk7, Bap1, Histone H4, Mybbp1A, Usp9Y and Peg10.
BAP1 is a tumour suppressor and a deubiquitinating enzyme, associated with processes such as
DNA repair, cellular differentiation, cell cycle and proliferation (Wang, Papneja et al. 2016). BAP1
has been identified to deubiquitinate several proteins like the breast cancer type 1 susceptibility
protein (BRCA1) and the host cell factor 1 (HCF-1) (Machida, Machida et al. 2009, Eletr and
Wilkinson 2011, Carbone, Yang et al. 2013). As ubiquitination of the v-cyclin, which is not in
complex with Cdk, has been shown to occur in HEK293 but not in BC-3 cells (Yoshioka, Noguchi
et al. 2010), BAP1 and v-cyclin interaction can be connected to either deubiquitination of v-cyclin
itself or its associating proteins.
According to the LC-MS/MS and WB analysis of the AP samples Cdk1 was the most abundant
protein amongst the novel v-cyclin interacting proteins. Moreover, the WB analysis indicated that
v-cyclin was specifically pulling down two isoforms of the Cdk1 protein (Figure 11, Cdk1 blot of
the vcyc1 and vcyc2 AP-eluates). Before mitosis Cdk1 is phosphorylated at Ser14 and Tyr15
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residues by Wee1 and Myt1 kinases to inactivate the Cdk1/cyclinB1 complex and when the cell
enters mitosis the Cdk1/cyclinB1 complex is de-phosphorylated by Cdc25 (Nigg 2001). Thus the
lower band in the Cdk1 blot could represent a nonphosphorylated and active form of the Cdk1
protein. Interestingly v-cyclin/Cdk6 has been shown to phosphorylate Cdc25a and enhance its
phosphatase activity (Mann, Child et al. 1999). Moreover, overexpression of v-cyclin dysregulates
mitosis and induces centrosome amplification and multinucleation (Verschuren, Klefstrom et al.
2002, Koopal, Furuhjelm et al. 2007). Thus it is possible that the v-cyclin/Cdk6 is activating the
Cdk1/cyclinB1 complex and in that way dysregulating the mitotic entry.
Cdk7 forms the Cdk-activating kinase (CAK) complex with cyclin H and ménage a trois 1 (Mat1),
which is required for the full kinase activity of CDK-cyclin complexes (Nigg 1996). Although the
kinase activity of the v-cyclin/Cdk6 complex does not require the CAK complex,
hyperphosphorylation of pRb and S-phase entry is fully accomplished only by the CAK
phosphorylated v-cyclin/Cdk6 complex (Child and Mann 2001, Kaldis, Ojala et al. 2001).
Additionally, the CAK complex is reported to protect the v-cyclin/Cdk6 complex from the p18INK4C
inhibition (Jeffrey, Tong et al. 2000). Thus the v-cyclin/Cdk7 interaction validated from the AP-LC-
MS/MS study could be due to the presence of the CAK-complex which supports the function of v-
cyclin/Cdk6 complex in promoting DNA replication. Another interesting finding has shown that
prior to the Cdc25 catalysed activation, Cdk1 needs to undergo additional activating
phosphorylation event by Cdk7 (Larochelle, Merrick et al. 2007). Thus in this case the v-cyclin
Cdk7 interaction could have a role in the activation of Cdk1 and in the observed dysregulation of
mitosis by v-cyclin.
Although v-cyclin is reported to bind multiple Cdks it is reported, however, to form functional
complexes only with Cdk2, Cdk6 and Cdk9 (Godden-Kent, Talbot et al. 1997, Mann, Child et al.
1999, Chang and Li 2008). This study identified the association of v-cyclin with two previously
unknown Cdks: Cdk1 and Cdk7. Therefore in the light of these results it could be speculated that v-
cyclin  might  have  a  high  binding  affinity  towards  several  Cdks  and  in  that  way  acts  like  a  Cdk
recruiter that enables virus-induced steering of the cell cycle.
CONCLUSIONS AND FUTURE PROSPECTS
70
CONCLUSIONS AND FUTURE PROSPECTS
This study focused on how a cancer-associated herpesvirus manipulates the pro- and anti-apoptotic
proteins of the host cell and utilizes the cell's stress response to secure efficient lytic replication.
Furthermore this study discovered comprehensive protein interactome of v-cyclin and cellular
proteins.
Research in this thesis identified that virally encoded miRNAs inhibit apoptosis by silencing the
expression of an effector caspase 3 in the latent KSHV-infected cells. In this study we were able to
discover a new cellular target of KSHV-encoded miRNAs and to uncover a novel anti-apoptotic
mechanism of this tumor virus. In the future it would be interesting to determine whether TinyLNA
oligos inhibiting miR-K12-1, K12-3 and K12-4-3p miRNAs sensitize KSHV-associated tumors to
etoposide or doxorubicin-induced apoptosis in a mouse model, which could provide new leads to
treat KS and PEL.
During  the  KSHV  latency  phase,  p53  is  kept  under  control  by  LANA  and  MDM2  to  allow  cell
proliferation and inhibit apoptosis. Results in this thesis provide new insights as to how KSHV can
cope with and utilize the p53 stress response during lytic reactivation. Accordingly, these results
demonstrate that at the early steps of the reactivation cascade, p53 is required to induce p21Cip-1-
mediated G2/M cell cycle arrest, probably to ensure adequate time for sufficient completion of the
lytic replication cycle. It remains to be seen whether cellular stresses such as hypoxia and oxidative
stress can activate the p53 response and aid the virus in efficiently completing the lytic cycle.
However, the p53 response can also lead to apoptosis during the lytic cycle and thus prevent release
of the viral progeny from the stressed cell. Nevertheless, premature apoptosis can be prevented by
anti-apoptotic viral and cellular proteins inhibiting the pro-apoptotic downstream targets of p53.
Importantly, our studies suggest that the survival of KSHV-infected cells is dependent on the
cellular anti-apopotic Mcl-1 protein. Furthermore, this thesis identified a potent anti-viral drug to
specifically target the lytic KSHV-infected cells. This study discovered that a pan Bcl-2 inhibitor,
Obatoclax, targeting both Mcl-1 and other Bcl-2 proteins, induces cell death in lytic phase KSHV-
infected cells. Hence, Obatoclax could be a promising new drug candidate to treat KSHV-
associated cancers. To study potential anti-viral effect of Obatoclax further it would be important to
address if Obatoclax can inhibit the release of viral progeny and test its potential anti-tumor effect
in PEL xenograft models.
With help of the isogenic and inducible v-cyclin expressing human cell line this study was able to
identify 8 novel v-cyclin interaction partners from which Cdk1, Cdk7 and Bap1 were successfully
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validated. Although the AP-LC-MS/MS method gives an easy and reliable snapshot of protein-
protein complex networks, it cannot distinguish direct interactions from the detailed biochemical
features of the protein complexes. To further identify the composition of the v-cyclin interacting
protein complexes, additional biochemical approaches such as size-exclusion chromatography,
immunoprecipitation or fluorescence resonance energy transfer (FRET) should be applied. Also
functional experiments to identify the biological role of these novel interactions for the virus-host
interaction  and  life  cycles  of  KSHV  and  in  the  context  of  the  other  viral  proteins  would  be
interesting to pursue.
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